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The bleak prognosis for individuals with metastatic cancer along with the 
substantial costs of treating the disease in its advanced stages are prompting clinical 
medicine to adopt a predictive and preventative modality of care.1  Targeted MRI contrast 
agents are anticipated to be critical tools in fully realizing the benefits of this new 
paradigm.1-3  Many approaches have been documented regarding both iron oxide contrast 
agents and the means of targeting them to specific tissues.4-49  The novel approach 
outlined in this dissertation employs functionalized poly(amidoamine) (PAMAM) 
dendrimers to effect specific uptake of superparamagnetic iron oxide nanoparticles 
(SPIONs) by cancer cells via the folate receptor.  The folate receptor provides an 
attractive internalization pathway because it is overexpressed on various types of 
epithelial cancer cells.50  More importantly, research has demonstrated that such cells also 
internalize acetamide-capped, folic acid-conjugated dendrimers via receptor-mediated 
endocytosis.51  The accompanying recycling of the receptor allows for internalization of 




Biological entities have been capable of producing endogenous uniform, 
crystalline magnetic nanoparticles (MNPs) for a very long time.56  The advent of interest 
in and research of such biogenic MNPs is credited to Lowenstam’s discovery in 1962 of 
magnetite (Fe3O4) in chitons (mollusks of the class Polyplacophora) and the verification 
of its biological origins.57  This finding was shocking because it contradicted the 
conventional notion that magnetite could only form under geological conditions.  
Through biomineralization processes, chitons are able to coat their radular denticles with 
a ferrihydrite precursor and subsequently convert at least a portion of the deposited 
mineral into a layer of aggregated fine magnetite crystals.58  The magnetite hardens the 
teeth of the tongue plate to enable their rasping action by which the mollusks scrape their 
food from rocks.  In addition, the magnetic character of these denticle caps may provide 
some insight57 into the navigational abilities observed in chitons.59, 60  Such a behavioral 
response to a stimulus, possibly rooted in the interaction of the magnetite nanocrystals 
with Earth’s geomagnetic field, is an example of magnetotaxis. 
In addition to chitons, many other organisms display magnetotaxis, and the only 
means of interacting with magnetic fields currently supported by conclusive evidence is 
through biogenic MNPs.61  Table 1.1 shows a sample of some of organisms in which 
magnetite nanocrystals have been found and their locales within the organisms.  Of these, 
only humans do not exhibit clear magnetotaxis;62 this does not, however, mean that the 
nanocrystals’ presence is biologically insignificant.  Since a connection has been show 
between neurodegenerative diseases and abnormal iron homeostasis in the brain, the 
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presence of magnetic iron oxide NPs may be linked to these disorders;56 they may also be 
related to epilepsy.62 
 
Table 1.1 - Organisms in which biogenic MPs have been found. 
Organism type Organism name Location of MPs 
Amphibians Eastern red-spotted newts throughout bodies63 
Birds Bobolinks upper beaks64-66 
 Homing pigeons upper beaks67-69 
Fish Atlantic salmon along lateral lines70 
 Rainbow trout olfactory lamellae71 
 Sockeye salmon ethmoid cartilage of skulls72, 73 
 Yellowfin tuna dermethmoid bone of skulls74 
Insects Honeybees abdomens75 
 Migratory ants thoraxes and abdomens76 
 Termites thoraxes and abdomens77 
Mammals Common Pacific dolphins dura maters78 
 Humans brains62, 79-81 
  hearts, spleens, and livers82 
Micro-organisms Magnetotactic bacteria magnetosomes83-85 
 Algae cells86 
Mollusks Chitons radular denticles57 
 
Among the remaining organisms in Table 1.1 that do seem to use their 
endogenous magnetic nanoparticles for navigation, magnetotactic bacteria have probably 
been the subjects of the most scientific inquiry.  Magnetotactic bacteria are Gram-
negative prokaryotes capable of synthesizing magnetite or greigite (Fe3S4) nanocrystals 
~100 nm in diameter.87  Each particle is encased in its own lipid bilayer vesicle, forming 
a particle-endosome composite called a magnetosome.  Since the net magnetic moments 
of isolated magnetite and greigite NPs are thermally randomized, magnetotactic bacteria 
generally organize magnetosomes in chains, leveraging cooperative magnetic effects to 
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form internal nanomagnets capable of interacting with the geomagnetic field.  This is 
useful to the organisms because all known magnetotactic bacteria are either 
microaerophiles or anaerobes: they proliferate in regions with low oxygen content.87  The 
bacteria’s internal nanomagnets passively torque them into alignment with Earth’s 
magnetic field.  Since the oxygen gradient is parallel to the vertical component of the 
geomagnetic field, the bacteria’s quests for their preferred conditions are constrained to 
efficient one-dimensional searches; the interaction also enhances efficiency by conferring 
stability on the organisms in their frequently turbulent aqueous environments.85  Similar 
benefits are presumably conferred to algae containing biogenic magnetic nanocrystals.86 
Excluding humans, all the higher-order organisms listed in Table 1 also display 
magnetotaxis.  Phillips et al. demonstrated magnetic homing in Eastern red-spotted 
newts.88  The animals—displaced from a point of origin while deprived of meaningful 
sensory stimuli during the displacement that could provide cues for their journey back—
were still able to return home.  Chitons57 and homing pigeons68 display similar behavior.  
Other animals may also leverage a “sixth-sense” magnetoreception to facilitate migration 
and foraging.64, 70, 75-77  The mechanisms of the magnetotaxis in these organisms are more 
complex than the passive torques magnetotactic bacteria experience but nevertheless 
seem to rely on interactions between endogenous MNPs and the geomagnetic field. 
1.3 Routes to Synthetic Magnetic anoparticles 
Although many organisms have long been able to produce uniform, crystalline 
MNPs using biochemical means, laboratory-based methods to produce comparable 
synthetic MNPs suitable for biological applications are relatively recent developments.89, 
90  There are both physical (“top-down”) and wet-chemical (“bottom-up”) routes to 
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magnetic nanocrystals.  Examples of the top-down methods include milling bulk 
materials into fine powders in the presence of surfactants and electron-beam 
lithography.91-93 
Wet-chemical syntheses are currently far superior to top-down approaches.  
Bottom-up approaches are easier and more effective ways to produce MNPs of the 
quality and quantity desired for biomedical applications89, 94, 95: particles with well-
defined size, shape, and physicochemical properties.96, 97  Wet chemical routes offer 
unparalleled control over these important particle characteristics95, 98 and generally 
produce MNPs with more favorable magnetic properties.94  A few important bottom-up 
methods are coprecipitation, reverse micelles, and thermolysis of organometallic 
precursors in organic media.  An overview of typical particle properties as produced by 
the techniques is listed in Table 1.2.95, 98-100 
1.3.1 Coprecipitation 
In the context of synthesizing iron oxide nanoparticles, coprecipitation refers to 
the precipitation of Fe3+ (ferric) and Fe2+ (ferrous) ions in aqueous solution using a 
base.101  Although many variations exist, the approaches can be classified according to 
the salts used as precursors. 
1.3.1.1 Ferrous Salts Only 
When only ferrous salts are used as sources of iron ions, ferric ions must be 
produced in situ; a mild oxidant is introduced to convert some Fe2+ to Fe3+.  The reaction, 
which can be described as oxidative hydrolysis,102 is proposed to occur in three steps.103-




















































































































































































 2+ - 2Fe + 2OH  Fe(OH)→  (1.1) 
Part of the Fe(OH)2 is then oxidized to form a ferric oxyhydroxide intermediate: 
 12 2 2 223Fe(OH)  + O  Fe(OH)  + 2FeOOH + H O→  (1.2) 
Finally, magnetite is formed via the dehydration reaction between ferrous hydroxide and 
two equivalents of ferric oxyhydroxide: 
 2 3 4 2Fe(OH)  + 2FeOOH  Fe O  + 2H O→  (1.3) 
The typical procedure for such syntheses is to prepare an aqueous solution of ferrous salt 
and add it dropwise to alkaline media;106-108 however, it can also be performed by 
titrating the base with the metal.109 
1.3.1.2 Ferrous and Ferric Salts 
Base hydrolysis of a mixture of ferric and ferrous salts is probably the most 
common and most successful means of producing magnetite nanocrystals.  The reaction 
is proposed to ultimately proceed as described in Eq. (1.3) above.101, 103  It can be written 
in complete form as:110, 111 
 2+ 3+ - 2 2 3 4 2Fe  + 2Fe  + 8OH  Fe(OH)  + 2FeOOH + 2H O  Fe O  + 4H O→ →  (1.4) 
To conduct the synthesis, a solution containing the iron salts and an alkaline solution are 
prepared.  As with ferrous salts alone, the metal can be titrated with the base,112-125 or the 
base can be titrated with the metal.111, 126-137  Most authors report that an [Fe3+] to [Fe2+] 
ratio of 2:1 in the salts solution is optimal.111-123, 127-133  This stoichiometric ratio is 
important since deviations adversely impact the quality of the product.101, 136  However, 
both lower124, 125 and higher126, 134, 137 ratios have been used successfully. 
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1.3.1.3 Coprecipitation Advantages 
Coprecipitation is a facile and convenient way to prepare colloidal MNPs,98 and 
the reactions scale well to produce copious amounts of particles: ~10 g with yields 
around 85%.95, 102, 124, 131 
1.3.1.4 Coprecipitation Drawbacks and Challenges 
Although coprecipitation approaches yield large amounts of MNPs, the particles 
vary widely in size and shape.95, 98, 99  This lack of control over the product particles 
seems to be because only kinetic factors, e.g. precursor concentration, can be manipulated 
to influence growth.95   Lowering the concentration of the salts solution can improve 
product quality but reduces yields, thus undermining the high yield advantage of 
coprecipitation. 
1.3.2 Reverse Micelles 
Reverse micelles (RMs), which can occur when surfactants are dispersed in 
nonpolar solvents, are spherical aggregates of surfactant molecules with their hydrophilic 
groups at the core and their lipophilic groups facing the solvent.  When water is added to 
a reverse micelle solution, the RMs sequester it within their hydrophilic center to form an 
aqueous core.138  In addition to other factors, the core size depends on temperature and 
the relative concentration of water and surfactant.139  These water cores constitute “nano-
reactors” for coprecipitation reactions to occur and produce magnetite.114, 138-151  The 
benefit of the nano-reactors is that they impose thermodynamic and kinetic constraints 
that are not present in bulk coprecipitation; these constraints promote the formation of 
more uniform MNPs.95, 152 
 9 
1.3.2.1 Reverse Micelle Advantages 
The ability to modulate the size of the reverse micelles by adjusting a few simple 
parameters facilitates and enhances size control.  Reverse micelle cores also represent 
ideal, confined environments for coating reactions; the technique has been used to coat 
MNPs in situ with gold,153-157 silica,138, 147, 149, poly(ethylene glycol) (PEG)144 among 
others. 
1.3.2.2 Reverse Micelle Drawbacks and Challenges 
Reverse micelle methods are inefficient; large ratios of organic solvent to water 
are required to form nanoscale reverse micelles.98  Particles produced using the technique 
exhibit poor crystallinity.140, 158  Their size distribution is not as broad as those produced 
using bulk coprecipitation, but they are still polydisperse, most likely because of the poor 
nucleation kinetics associated with the typically low reaction temperatures.158  Also, the 
surfactants need to be removed following synthesis to modify the particles’ surfaces, 
often leading to aggregation.148  Finally, reverse micelle techniques require judicious 
selection of the reactants since the wrong choice might compromise the integrity of the 
RMs.146 
1.3.3 Thermolysis in Organic Media 
Under appropriate solvent and surfactant conditions, heat can be used to 
decompose organometallic precursors in organic media to form monodisperse 
populations of iron oxide nanoparticles.  Such approaches were first applied to synthesize 
semiconductor quantum dots and were only recently extended to transition metal 
oxides.159, 160  A sampling of these developments is listed in Table 1.3. 
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Table 1.3 - Thermolytic decomposition syntheses of iron oxide nanoparticles. 
Precursor Surfactant Solvent Other Reagents Temperature 
Fe(acac)3 hexadecylamine hexadecylamine  250ºC161 
 oleic acid, oleylamine benzyl ether 1,2-hexadecanediol reductant 300ºC162, 163 
Fe(CO)5 oleic acid octyl ether (CH3)3NO oxidant 300ºC164 
 lauric acid octyl ether (CH3)3NO oxidant 300ºC164 
 lauric acid trioctylamine PyO oxidant 296ºC165 
 lauric acid octyl ether PyO oxidant 296ºC165 
 lauric acid phenyl ether PyO oxidant 256ºC165 
 stearic acid octyl ether (CH3)3NO oxidant 290ºC166 
FeCup3 trioctylamine trioctylamine  250ºC160 
Fe(OAc)2 oleic acid trioctylamine  255ºC165 
FeO(OH) oleic acid 1-octadecene  320ºC159 
iron oleate oleic acid 1-octadecene  300ºC167 
 oleic acid 1-octadecene  320ºC168 
 
In their pioneering work, Alivisatos’ group demonstrated the ferric cupferron 
complex (FeCup3, where “Cup” represents -nitrosophenylhydroxylamine) to be a 
suitable precursor to produce uniform maghemite nanoparticles.160  The complex was 
synthesized by the precipitation of ferric ions under acidic conditions using cupferron.  It 
was then purified and dissolved in octylamine to form a stable solution.  This solution 
was injected into a rapidly stirring solution of trioctylamine, at 300°C.  Trioctylamine is a 
coordinating solvent: it acts as a surfactant to coat the particles in situ in addition to being 
the dispersion medium. The colorless trioctylamine solution immediately turned black 
upon injection, indicating the decomposition of the FeCup3 complex and the formation of 
nanocrystals.  After aging at 225°C for 30 minutes, the reaction mixture was allowed to 
cool.  The product nanoparticles could be isolated from this reaction mixture by the 
addition of excess volumes of acetone or other polar solvents and could then be 
 11 
resuspended in nonpolar solvents like hexanes.  Size control was possible by tuning 
reaction temperatures and the relative proportions of solvent and precursor. 
Iron oleate is another aftermarket precursor that has been synthesized and 
employed to prepare iron oxide nanocrystals, as Peng’s group recently reported.167  They 
used 1-octadecene, a noncoordinating solvent, with oleic acid as the surfactant.  Very 
similar work was done by Hyeon and coworkers in verifying their hypothesis that iron 
oleate was the intermediate product acting as the precursor when they began their 
reaction with iron pentacarbonyl, Fe(CO)5.  Their first study used Fe(CO)5 with oleic acid 
as the surfactant along with a mild oxidant in octyl ether to produce iron oxide 
nanocrystals.164  In subsequent work, they obtained very favorable results by first 
synthesizing the iron oleate complex rather than having it form in situ; oleic acid and 1-
octadecence were the surfactant and solvent, respectively.168 
One final notable precursor is iron (III) acetylacetonate, Fe(acac)3.  Sun and 
colleagues were the first to report the use of Fe(acac)3 as a precursor for iron oxide 
nanoparticles.162, 163  Their strategy involved long-chain diols as mild reductants along 
with oleic acid and oleylamine as surfactants dissolved in benzyl ether.  The mixture was 
ultimately heated to 265°C and aged at that temperature for 30 minutes to produce 
monodisperse magnetic nanocrystals that could be precipitated, isolated, and redissolved 
in nonpolar organic solvents. 
1.3.3.1 Thermolysis in Organic Media Advantages 
Thermal decomposition of organometallic precursors in organic solvents is 
arguably the best current route to iron oxide nanoparticles.  It offers the highest level of 
control over the size, shape, and morphology of the product,98 consistently producing 
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monodisperse populations of particles.  The elevated reaction temperature helps eliminate 
crystal defects, resulting in highly crystalline structures and consequently more favorable 
magnetic properties.158, 169  Yields are also high, so large quantities of high-quality 
particles can be produced:98 a 40 g reaction has been reported by Park et al.168 
1.3.3.2 Thermolysis in Organic Media Drawbacks and Challenges 
Iron oxide nanocrystals produced by thermolytic methods exhibit superior 
characteristics, but they are necessarily capped by long-chain organic surfactants and are 
therefore not biocompatible as synthesized.100  In addition, the synthetic procedures 
themselves are elaborate and can be unexpectedly difficult to execute successfully.98 
1.4 Properties of Magnetic anoparticles 
1.4.1 “Magnetic” 
In its common use, “magnetic” refers to the more specific phenomena called 
ferromagnetism and ferrimagnetism.95  Ferro- and ferrimagnetism are, however, only two 
of several classes of magnetic response.  Strictly speaking, magnetic phenomena are 
purely quantum mechanical and are rooted in the spin and orbital angular momenta of 
electrons.  It is helpful to briefly discuss at least some of the varieties of magnetism and 
their underlying principles. 
1.4.1.1 Diamagnetism 
All materials exhibit diamagnetism, but the effects are frequently negligible 
compared to those of the other forms of magnetism.  The diamagnetic response is linked 
to the orbital motion of electrons about atomic nuclei and can be understood by viewing 
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these motions as forming small current loops.  Per Lenz’s law, the orbital motion of the 
electrons will be altered when placed in a magnetic field to produce currents and 
accompanying magnetic fields that oppose the magnetic flux through the loops.  The 
action against the applied field means that diamagnetic materials have a negative 
magnetic susceptibility.  Their associated magnetic moments are antiparallel to the 
applied field, and this response is very small: diamagnetic susceptibilities are only around 
-10-6.170  Furthermore, the effect is not permanent; the moments and the ordering among 
them vanish in field-free conditions.171 
1.4.1.2 Paramagnetism 
Only materials composed of atoms or molecules having unpaired electrons are 
paramagnetic.  Paramagnetism is due to the spin and orbital angular momenta of these 
unpaired electrons.95, 172  The magnetic moments of individual paramagnetic atoms in a 
material are only weakly coupled to each other, and room temperature thermal energy is 
sufficient to overcome these interactions to eliminate any net magnetic moment.171  When 
placed in a magnetic field, a small fraction of the atomic moments align parallel to the 
field in accord with the Boltzmann distribution95; conducting the analysis leads to the 
magnetization, M, of the sample in terms of the Langevin function, L, and the saturation 
magnetization, Ms: 
 ( ) ( )sM H M L H=  (1.5) 
The Langevin function is: 










where µ is the atomic moment, H is the applied field, k is Boltzmann’s constant, and T is 
the absolute temperature.  Similar to the case of diamagnetism, the paramagnetic 
interaction with the field is weak and disappears in the absence of an applied field.  
Paramagnetic susceptibilities are also small, but they are positive: ~10-6.95  Paramagnetic 
atoms are further unlike diamagnetic atoms because the moments of individual 
paramagnetic atoms persist in field-free conditions; it is only the ordering among them 
that disappears due to thermal fluctuations. 
1.4.1.3 Ferromagnetism and Ferrimagnetism 
The constituents of ferromagnetic materials are paramagnetic species arranged in 
a lattice such that they strongly interact with each other to establish permanent alignment 
of their dipole moments even in the absence of an applied magnetic field: they have a 
remanent magnetization or “exhibit remanence.”  The parallel alignment among moments 
is contrary to the notions of classical electromagnetism that predict adjacent dipoles will 
align antiparallel to each other.  Quantum mechanics, however, provides an 
understanding of the phenomenon through exchange interactions.  Electrons, which are 
fermions, are responsible for the dipole moments of paramagnetic atoms.  Fermionic 
wave functions are antisymmetric under particle exchange.  This condition favors 
alignment of the dipoles since such a configuration places electrons in different orbitals 
and actually lowers the Coulombic repulsion between them, thus reducing the energy of 
the system; the “exchange energy” is said to be minimized.172 
Ferrimagnetism is nearly identical to ferromagnetism with the exception that it 
occurs when different paramagnetic species composing a material exist in sublattices.  
The moments within each sublattice are cooperatively aligned due to exchange 
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interactions, but the net moments of the sublattices are antiparallel to each other.  A net 
magnetic moment still exists when these moments are unequal.  (The phenomenon of 
antiferromagnetism occurs when the moments among sublattices sum to zero.)  Because 
of this competition between sublattices, the magnetic moments of ferrimagnetic materials 
are typically lower than those of ferromagnetic materials. 
Despite the difference in the magnitude of the magnetic moments between ferro- 
and ferrimagnetic materials and the subtle distinction underlying their moments, the 
materials behave similarly.  One very important shared property is that the long-range 
ordering between the constituent paramagnetic species does not extend throughout the 
bulk.  In bulk materials it is energetically favorable to establish regions of uniform 
magnetization without the moments of the regions being aligned.173  These regions are 
called domains, and they are separated by barriers called domain walls.  Although it costs 
energy to form domain walls, the reduction in magnetic energy realized by their 
formation yields a net energetic benefit for bulk materials. 
Virgin ferro- and ferrimagnetic materials actually display no net magnetization in 
field-free conditions due to the arrangement of domains; there is still ordering within the 
domains but no overall magnetic order.  When ferro- and ferrimagnetic materials become 
magnetized by an applied field, the domains along its direction grow at the expense of the 
other domains to produce a net moment.  As might be expected, this magnetic response is 
much larger than what is observed for paramagnets.  Ferro- and ferrimagnetic materials 
are characterized by high susceptibilities ~106. 
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1.4.1.4 Superparamagnetism 
When ferro- and ferrimagnetic materials become very small, establishing domains 
costs more energy than the reduction in magnetostatic energy they would afford.174  In 
this regime, particles thus exist as single domains.  The size where monodomain structure 
begins to occur, referred to as the critical diameter, is typically ~10-100 nm but depends 
on the material98, 174; it is about 70 nm for Fe3O4.
175  In monodomain particles, all the 
constituent paramagnetic moments are aligned.96, 176-178  Changes in magnetization can 
obviously no longer occur by rearrangement of domain walls since none exist.  The 
particle moment, which theoretically consists of the entire complement of atomic 
moments, changes in response to an applied magnetic field either via coherent rotation of 
the moments themselves (Néel relaxation) or via physical rotation of the particle 
(Brownian relaxation).179-181 
After the applied field is removed, large monodomain particles retain a net 
moment, and this remanent magnetization lies along an easy axis.  Easy axes are certain 
preferred directions of magnetization corresponding to energy minima; the lack of 
equivalence among all possible moment orientation is called magnetic anisotropy.  Many 
easy axes can exist separated by energy barriers.  There are various sources of anisotropy 
and the corresponding barriers, but size is among the most critical factors involved. 
Once particles become much smaller than the maximum monodomain size, the 
energy separating easy axes becomes comparable to ambient thermal energy.152  The 
magnetic moment of the particle thus undergoes spontaneous Néel relaxation and 
continuously cycles through the easy directions.100, 182, 183  These thermal fluctuations 








=  (1.7) 
where Eb is the height of the energy barrier, k is Boltzmann’s constant, T is the absolute 
temperature, and f0 is an attempt frequency 10
9-1012 Hz96, 180: a quantity proposed to be 
linked to the gyromagnetic precession frequency of a particle’s moment in the effective 
anisotropy field.96, 184, 185  Due to the persistent fluctuation of their magnetic moment, 
particles of this size do not exhibit remanence unless the measurement can be made faster 
than the frequency of transitions.  They therefore behave like singular paramagnetic 
species but with important distinctions.  The magnetic moment of such a particle is the 
sum of thousands of paramagnetic moments.  In an applied magnetic field, these “super-
moments” will align just like very large individual paramagnetic moments: they are 
“super-paramagnets” and exhibit the phenomenon known as superparamagnetism.177  The 
magnetization behavior of a collection of monodisperse superparamagnetic particles in an 
applied field can be conveniently described using the Langevin function:173, 186 
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 (1.8) 
where Ms is the saturation magnetization, µ is now the per-particle moment, H is the 
applied field, k is Boltzmann’s constant, and T is the absolute temperature. Collections of 
superparamagnetic particles exhibit saturation magnetizations that are comparable to but 
smaller than those of the corresponding bulk if the parent material is ferrimagnetic.174  
The saturation magnetizations of collections of particles whose bulk parent material is 
ferromagnetic may actually be slightly enhanced with respect to the bulk value.174  These 
phenomena are due to surface effects, size effects, or, more likely the interplay between 
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them98, 187; many excellent articles have been written containing thorough discussions and 
debate about the topic.96, 126, 172, 174, 175, 187-200 
1.4.2 “Nano” 
The small size of SPIONs leads to their fascinating magnetic properties that allow 
them to be addressed and manipulated by magnetic fields, but it is also a useful and 
essential feature for their applications in biology.  Nanoparticles can be dispersed to form 
stable, uniform colloids suitable for injection.100, 128, 179  Once in vivo their size facilitates 
widespread tissular diffusion to encounter many different biological structures.1, 54, 128  
Particles smaller than around 6 nm can extravasate through the continuous capillaries of 
tissues like muscle, lung, and skin.201-203  With diameters below 20 nm, particles are able 
to pass through blood vessel walls.204  Larger particles up to 60 nm can still penetrate 
fenestrated capillaries found in different regions, e.g. the kidney, pancreas, and intestines, 
but are susceptible to rapid splenic filtration.201-205  Because nanoparticle dimensions are 
similar to biological structures, the particles are able to directly interact with such 
entities.94, 97, 100, 170, 206-208  Furthermore, the particles’ large relative surface area presents 
ample space to carry multiple copies of biofunctional molecules to moderate these 
interactions.128, 179, 206 
1.5 Biomedical Applications of Magnetic anoparticles 
1.5.1 Targeting Therapeutics 
The systemic distribution of therapeutics in contemporary treatment methods is 
problematic and represents a major flaw that can make the difference between success 
and failure.209  High doses are often needed to accumulate adequate amounts of 
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therapeutic at the target site, but larger doses also mean higher risk of adverse side-effects 
and elevated toxicity to non-target sites.210, 211  A strategy to address these issues, fostered 
by several researchers in the late 1970s,212-214 is to magnetically label therapeutics so they 
can be targeted to a region of interest using an external magnetic field.  The field confines 
drugs longer in the target region to boost efficacy.90, 215-219  Therefore, more substantial 
therapeutic effects can be realized at lower doses while minimizing risk to healthy 
tissues.170, 215, 220  Magnetic targeting of therapeutics has been examined regarding the 
more fundamental issues of carrier composition and biodistribution212, 221-225 in addition 
to being applied in studies in vitro and in vivo.213, 215, 217-219, 226-234  A sampling of the latter 
studies is listed in Table 1.4.  Reviews addressing the topic have also been written.211, 216 
Recent in vivo work in the field of magnetic drug targeting has been successful 
although many challenges remain.209, 216, 235  The major obstacle when using an external 
magnet to target particles in vivo is the rapid decrease of field strength with increasing 
distance from the magnet because strong fields are required to overcome forces from 
blood flow and hold the particles at the target site.209, 236  This imposes a major limitation 
for use in humans as locations deeper than about 2 cm within the body are poorly 




Table 1.4 - Applications of iron oxide nanoparticles in magnetically targeted therapeutics. 
Animal Therapeutic Class Therapeutic ame 
[in vitro] drug adriamycin213, 234 
 radionuclide rhenium-188228 
human drug doxorubicin230, 232 
 drug epirubicin218, 219 
mouse gene vector recombinant adeno-associated virus 2231 
 radionuclide yttrium-90229 
rabbit drug methotrexate215 
rat drug adriamycin226 
 drug doxorubicin233 
 drug epirubicin217 
swine drug doxorubicin227 
 
1.5.2 Magnetic Resonance Imaging (MRI) Contrast Agents 
Magnetic resonance imaging is among the best clinical diagnostic tools currently 
available.52, 54, 238  It is a noninvasive, tomographic technique, without the dangers of 
ionizing radiation, that offers superb spatial resolution,1, 9, 53, 55 perhaps even down to the 
cellular or subcellular level.3  The largest contributors to MRI signal for biological 
applications are the hydrogen nuclei (protons) in water molecules.  In a simplistic sense, 
MRI is just the application of proton nuclear magnetic resonance (NMR) to biological 
systems:56 it yields intensity maps of water proton spin relaxation in tissue.  Contrast in 
the resulting images is the consequence of proton density and relaxation time constants 
that vary throughout the sample.  However, MRI suffers from relatively low sensitivity 
that limits its utility when relying solely upon these inherent contrast mechanisms.111  
This flaw can fortunately be addressed using exogenous magnetic agents that influence 
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local proton spin relaxation dynamics thereby enhancing the distinguishability of 
structures within images.53, 170, 238-241 
There are several different types of contrast agents, and the two main classes are 
based on chelated paramagnetic ions, such as gadolinium (Gd), or SPIONs.  Particulate 
superparamagnetic contrast agents offer advantages over their paramagnetic counterparts 
in both efficiency and mechanism of action.  Whereas chelated paramagnetic ions must 
be present at the mM level to generate appreciable contrast, SPIONs are detectable at the 
nM concentrations or lower.242, 243  The action of SPIONs is also not as critically 
dependent on their surroundings.  Paramagnetic chelates produce local effects that are 
mediated by exchange of water protons, but SPIONs produce magnetic field gradients 
and corresponding changes in tissue susceptibility that impact a larger region without the 
need for direct contact with water flux.52, 202, 238, 244 
A plethora of studies have examined the theory and use of SPION contrast agents; 
some of these investigations are presented in Table 1.5.  These applications leverage the 
passive targeting of SPIONs in vivo that is a function of their physicochemical 
characteristics; the particles’ biodistribution can be tuned by adjusting parameters such as 
their size, surface coating, and surface charge.176, 245  Most of the targeting involves the 
reticuloendothelial system (RES), also known as the mononuclear phagocyte system 
(MPS): an array of phagocytic cells intended to defend against foreign matter in the 
circulatory system.54  Contrast arises due to the disparity in accumulation of SPIONs 
resulting from the reduced or eliminated RES function of pathologic versus healthy 
tissue.246  Larger particles are most useful for targeting the secondary lymphoid organs of 
the RES, e.g. the liver and the spleen.176, 245  Particles with longer circulation, which are 
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generally smaller, accumulate in the lymph nodes and bone marrow and can even be 
addressed to sites of inflammation by macrophage uptake.176, 245  Small particles can also 
be used as blood pool agents for imaging the vasculature and have the potential to gather 
in non-RES tumors.176, 245  Such passive tumor targeting is the result of the enhanced 
permeation and retention effect.  Malignancies exhibit leaky vasculature and poor 
drainage.247  Once particles reach the tumor site, they extravasate through the porous 
endothelium and are retained by the tumor due to its compromised clearance 
mechanisms.201, 203, 248-252 
 
Table 1.5 - Applications of iron oxide nanoparticles as passively targeted MRI contrast agents. 
Targeting Mediator Subject Region of Interest 
[blood pool] human aortoiliac vessel253 
  coronary artery254 
 rabbit vasculature255 
 rat vasculature256 
EPR human breast tumor257 
 rat brain tumor258, 259 
  breast tumor260 
macrophages mouse joint inflammation261 
 rabbit atherosclerosis262, 263 
 rat central nervous system inflammation264 
  kidney allograft265 
RES human bone marrow266, 267 
  liver268-271 
  liver and spleen272 
  lymph nodes273-275 
 rabbit liver and spleen276 
 rat bone marrow277 
  liver278 
  liver and spleen246 
  lymph nodes279-283 
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1.5.3 Actively Targeted MRI Contrast Agents 
Although the physical mode of targeting employed for therapeutic delivery and 
the passive mode of targeting used for current clinical SPION contrast agents are very 
useful, further enhancement of specificity is necessary to realize the agents’ full 
diagnostic potential.284  The vision is to construct agents that can be addressed to very 
specific molecular markers of pathology so diseases can be visualized and diagnosed 
earlier and more accurately and treated more effectively or even prevented, ultimately 
improving patient survival.1, 2, 285  Such an approach, leveraging molecular interactions, is 
called active targeting. 
Many different agents (Table 1.6) have been used to actively target SPIONs, and 
antibodies have been a frequent choice.4-17.  Funovics and co-workers used 
coprecipitation methods to generate targeted dextran-coated particles.7  One half of the 
batch was decorated with anti-her2/neu monoclonal antibodies (mAbs); the other half 
was functionalized with mAbs directed against the 9.2.27 tumor antigen.  The researchers 
demonstrated in vitro SPION targeting via both these vectors in numerous cell lines using 
SPIONs labeled with isotype antibodies, untreated cells and antigen-negative cells as 
controls. 
Cheon’s group recently published combined in vitro and in vivo results using anti-
her2/neu mAb as a targeting moiety.9  The investigators synthesized uniform SPIONs in 
organic solvents and transferred them into water via place exchange with the small 
molecule dimercaptosuccinic acid (DMSA); Herceptin molecules were subsequently 
linked to free thiol functions on the nanoparticle surface.  Targeting of the conjugates was 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































MRI signal intensity of cell samples was observed to drop with increasing expression.  
SPIONs labeled with irrelevant antibody and untreated cells served as controls.  The 
probes were also investigated in two mice, each bearing a NIH3T6.7 xenograft.  One 
mouse was injected with the Herceptin conjugates, and the other was similarly treated 
with SPIONs bearing the irrelevant antibody.  The former animal’s tumor rapidly became 
hypointense on T2*-weighted images, whereas images of the tumor in the latter animal 
exhibited virtually no change. 
In addition to antibodies, the glycoprotein transferrin has been used as a targeting 
moiety for SPIONs.38-42  The transferrin receptor is a particularly interesting choice 
because, as the name suggests, it is used to transport iron contained by the protein into 
cells.  Following internalization, the receptors are recycled to the cell surface for further 
iron accretion.  This cycle is therefore useful in loading transferrin-decorated particles 
into cells via receptor-mediated endocytosis leading the potential for particle 
accumulation, enhanced relaxation effects and consequently higher contrast. 
1.6 Dendrimer-Coated SPIOs as Actively Targeted MRI Contrast 
Agents 
1.6.1 Why Thermolysis? – Quality and control 
Thermolytic decomposition methods are challenging and produce particles that 
require additional processing to be made biocompatible for use in medicine, but their 
characteristics and the control over them are unparalleled by other contemporary products 
and techniques.98  The monodispersity and high saturation magnetization achieved are 
both essential to their use as targeted MRI contrast agents.100  The particles’ large 
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magnetic response maximizes contrast effects at minimal doses.  Their narrow size 
distribution is critical for the understanding and optimization of behavior in vivo as well 
as facilitating comparisons among batches and formulations.94, 176, 220 
1.6.2 Why Iron Oxide? – Safe but highly effective 
Many factors make iron oxides (Fe3O4 and maghemite, γ-Fe2O3) excellent 
materials for developing targeted MRI contrast agents.  They have been shown to 
naturally occur in many animals and are currently the only inorganic particulate contrast 
agents approved for in vivo human applications with more formulations now in Phase-III 
trials.244, 286, 287  Iron oxides are biodegradable and exhibit neither acute nor chronic 
toxicity.99, 176, 284, 288  Uncoated magnetite has an LD50 of 300-600 mg Fe per kg body 
weight, and biocompatible coatings can improve this by an order of magnitude.52, 289 
Superparamagnetic iron oxide nanoparticles have exceptional magnetic 
properties, so they are able to generate sufficient contrast in low doses versus their 
paramagnetic counterparts, like gadolinium (Gd): nM SPIONs (µM Fe) versus mM 
Gd.176, 242, 243  The typical clinical contrast agent dose for SPIONs of 1 mg Fe per kg body 
weight is a small fraction of the LD50.  It is also negligible compared to the 
approximately 3500 mg of total iron naturally occurring in various forms in the human 
body, representing less iron content than is contained in a pint of blood.290, 291  
Furthermore, the body has established methods to metabolize the excess iron introduced 
by the particles.202, 203, 239, 281, 284, 292 
Although contrast agents based on strong ferromagnetic parent materials like 
cobalt and nickel are attractive, they are toxic in pristine and oxidized forms and are not 
biodegradable.94, 183, 293-295  Pure iron nanoparticles certainly represent a possible 
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alternative, but metallic particles are highly unstable and readily oxidize without robust 
protection;153, 175, 296 they sometimes react so strongly that they spontaneously ignite in 
air.152  Magnetite is also susceptible to oxidation into maghemite; however, this transition 
occurs without appreciable alteration of magnetic properties.171, 297 
1.6.3 Why Dendrimers? – Uniform, proven biocompatible coating 
Poly(amidoamine) (PAMAM) dendrimers are hydrophilic, biocompatible, 
monodisperse, cascade-branched macromolecules with highly flexible surface chemistry 
that facilitates functionalization.298-300  They can be used as uniform scaffolds carrying 
multiple copies of biologically relevant molecules without interfering with the 
components’ functions.301, 302  Their well-defined, consistent structure is crucial to their 
successful and reproducible use as carriers;252 it also makes them particularly well-suited 
for interaction with biological entities because it emulates the inherent order of natural 
macromolecules.303 
Our group has demonstrated success using PAMAM dendrimers to target tumors 
both in vitro and in vivo.51, 299, 304-312  The PAMAM dendrimers used for the work 
described in this dissertation are unique in that the surfaces were completely neutralized 
by capping with acetyl groups following the covalent attachment of several molecules of 
both folic acid and 6-TAMRA dye.  Folic acid is the targeting moiety; the dye allows 
optical tracking of the devices, and the neutral surface minimizes nonspecific interactions 
with cells.299, 300, 304, 308, 312, 313  The dendrimers imparted targeting and fluorescence to the 
SPION cores in addition to protecting them from aggregation.  Such a thick, hydrophilic 
coating relying on steric hindrance to keep the cores isolated is expected to provide 
enhanced stability as well as longer circulation times in vivo.99, 100, 252, 314 
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1.6.4 Why Folic Acid? – Small, effective agent linked to fundamental processes 
Folic acid (FA) is excellent as a targeting moiety for several reasons.  Folic acid is 
a low molecular-weight B-vitamin whose receptors are overexpressed by an array of 
cancers,50, 315 including lung316, breast316, colon316, choroid plexus brain316, 
choriocarcinoma316, and ovarian cancers.316-319  Folic acid receptors (FARs) tend to occur 
in clusters,251 and this morphology can be leveraged for multivalent interactions leading 
to enhanced targeting efficacy by using multiple folic acid moieties on the nanoparticle 
surface.52, 305, 320  Although normal tissues also express FARs, the level of expression is 
much higher in malignant tissue and seems to increase as the cancer progresses.321  The 
FARs on normal cells are also expressed in a different location that is not accessible from 
the bloodstream.321  
Folic acid is a stable molecule that does not induce an immune response, 
presumably because of its small size.25, 50, 52, 252  Its small size also facilitates tissular 
diffusion and increases residence time in the blood compartment, especially versus 
antibodies.52, 285  Also unlike antibodies, FA has a high affinity for its target that does not 
diminish following conjugation to macromolecules or nanoparticles.50, 285  A third and 
very important advantage of FA over antibodies is that FARs are expected to be more 
stable targets, whereas antigen expression may change over time.  This is because FA is a 
necessary ingredient in crucial biosyntheses underlying cellular proliferation.22, 238, 244, 285  
Folic acid receptors are therefore internalized and recycled to the surface for gathering 
the vitamin,22, 25, 251 a process that is highly advantageous since it should enable active 
loading of SPIONs and lead to MRI signal enhancement.4, 52-55 
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1.6.5 Hypotheses and Specific Aims 
This dissertation work focused on exploring the possibility of SPIONs as targeted 
MRI contrast agents.  The project was driven by these hypotheses: 
1.) Thermolytic decomposition is the optimal method to produce high-quality 
SPIONs. 
2.) Appropriately functionalized dendrimers will transfer SPIONs from organic 
media, solubilize and protect them in biological environments, and impart 
targeting. 
3.) The KB cell line with an overexpression of the folate receptor provides a valid 
test case to prove the concept of targeting SPIONss using dendrimers. 
4.) Folic acid-labeled dendrimer-SPION conjugates will target KB cells in vitro. 
The novel research that I conducted to address these hypotheses had these specific aims: 
1.) Synthesize high-quality SPIONs in organic media (OC-SPIONs). 
2.) Solubilize high-quality magnetic nanocrystals in biological media using 
dendrimers that are conjugated to folic acid to effect targeting. 
3.) Characterize organic-coated SPIONs and dendrimer-coated SPIONs (DC-
SPIONs). 
4.) Conduct biological experiments to verify targeting of DC-SPIONs in vitro 
using the fluorescent tag on the dendrimers as well as the elemental signature 
from the iron oxide core. 
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CHAPTER 2  
 
SYTHESIS OF ORGAIC- AD DEDRIMER-COATED 
IRO OXIDE AOPARTICLES 
 
2.1 Introduction 
2.1.1 Poly(amidoamine) (PAMAM) Dendrimers 
Our group has demonstrated success using poly(amidoamine) (PAMAM) 
dendrimers conjugated with FA to target tumors both in vitro and in vivo.1-9  PAMAM 
dendrimers are biocompatible, cascade-branched macromolecules with highly flexible 
surface chemistry that facilitates functionalization.  The PAMAM dendrimers used in this 
work are unique in that the surfaces were completely neutralized by capping with acetyl 
groups following the covalent attachment of several molecules of both folic acid and 6-
TAMRA dye.  Folic acid is the targeting moiety; the dye allows optical tracking of the 
devices, and the neutral surface minimizes non-specific interactions with cells.1, 5, 10-13  
Targeting efficacy is further augmented by the multivalent effect—multiple FA moieties 
simultaneously interacting with multiple receptors—exhibited by the dendrimer-FA 
conjugates.2 
2.1.2 Iron Oxide Nanoparticles 
For use in biomedical applications, magnetic nanoparticles should possess 
uniform, carefully controlled physicochemical and magnetic properties since the 
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particles’ behavior critically depends on these characteristics.14-17  Indeed, it is only 
justifiable to refer to the singular behavior of the particles if they are monodisperse; 
otherwise, “particles’ behaviors” is more appropriate.  Synthesizing monodisperse 
populations of highly crystalline magnetic nanoparticles is a very complicated task.18  
Size control is challenging because the high surface energy of nanoparticles favors 
agglomeration and nonuniform growth both immediately following formation of 
nucleation centers and as the particles age in solution.19  Nucleation occurs to restore 
thermodynamic equilibrium when the reaction solution becomes supersaturated with 
precursors or their decomposition products.20  The growth of small particles is dominated 
by this process as precursor molecules react and condense.  As particles become larger, 
they grow at the expense of other particles through Ostwald ripening: material is removed 
and redistributed among particles.20  The key to forming monodisperse particles is, 
therefore, to separate nucleation and growth: a single burst of nucleation followed by 
slow, steady growth of the nuclei.21, 22  This can be accomplished by using a single pure 
precursor that exhibits a sharp decomposition temperature and injecting it into a suitable 
surfactant solution.20, 21  The surfactant immediately caps the nucleation centers as they 
form and modulates their growth. 
Initial iron oxide nanoparticle syntheses were conducted following the procedure 
published by Rockenberger et al.  It was discovered, however, that the product particles 
were difficult to purify and redissolve following purification; other groups reported 
similar problems with handling.23  The nanoparticles were readily precipitated by adding 
several excess volumes of more polar solvents miscible with the organic dispersion 
media, e.g. acetone and ethanol; flocculation was evident as the liquid went from clear 
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and brown to turbid and brown.  However, the precipitated particles did not settle very 
well even when a rare-earth magnet was used to facilitate the process.  Once the particles 
were finally magnetically isolated from the supernatant, purification by rinsing with the 
precipitating solvent made the majority of the particles insoluble.  This suggests that the 
amine surfactants used were very weakly interacting with the particles’ surfaces and 
could therefore be stripped away via simple solvent washes. 
I hypothesized that oleic acid would increase the particles’ stability and make 
them more tractable.  Experimentation verified this hypothesis.  Recent literature also 
provides support as it indicates oleic acid is the optimal capping agent for iron oxide 
nanoparticles.24, 25  This is presumably due to the strong coordination of carboxylic acids 
to nanoscale metal oxide surfaces26 as well as a particular feature of oleic acid: the kink 
in its aliphatic hydrocarbon tail at the double bond.27 
2.2 Reagents and Materials 
Reagents were used as obtained from commercial sources.  Hexanes (HPLC 
grade), dimethyl sulfoxide (DMSO, >99.8%), methanol (MeOH, HPLC grade), 
hydrochloric acid (certified ACS Plus) and acetone (>99.5%) were purchased from Fisher 
Scientific (Chicago, IL); 6-carboxytetramethylrhodamine, succinimidyl ester *single 
isomer* (6-TAMRA, 6T) was from Molecular Probes, Inc. (Eugene, OR).  Ferric 
chloride hexahydrate (FeCl3·6H2O, >98%) and folic acid (FA, 98%) were acquired from 
Sigma (St. Louis, MO).  Chloroform (>99.8%), cupferron (97%), acetic anhydride 
(99.5%), -(3-dimethylaminopropyl)-′-ethylcarbodiimide hydrochloride (EDC, 98%), 
triethylamine (Et3N, >99.5%), octylamine (99%), trioctylamine (98%), oleic acid 
(technical grade, 90%) and sodium bicarbonate (>99.5%) were from Sigma-Aldrich 
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(Milwaukee, WI).  Amine-terminated generation 5 PAMAM dendrimers (G5-NH2) were 
purchased from Dendritech (Midland, MI) and purified via dialysis and ultrafiltration.3, 10  
The polymer was checked for the presence of trailing generations by HPLC,5, 28 and 
characterized by GPC5, 29 and MALDI-TOF30, 31 to establish the molecular weight.  The 
number of primary amine terminal functional groups was determined to be 110 by 
potentiometric titration.4, 30  Throughout the experiments unless otherwise specified, 
ultrapure water with a resistivity of at least 18 MΩ·cm was used as produced by a Milli-
Q purification system (Millipore; Bedford, MA). 
2.3 Dendrimer Conjugation 
The PAMAM dendrimers used in this study were modified according to 
previously published protocols.  Acetylation was conducted on G5-NH2 to neutralize an 
average of 73% (82 out of 110) of the dendrimers’ amine termini to produce G5-Ac(82).5, 
29  This step is essential for minimizing non-specific interactions with cells.1, 5, 10-13  Next, 
EDC coupling was employed to conjugate the targeting moiety, folic acid, at an average 
of 5 molecules per dendrimer to yield G5-NH2(23)-Ac(82)-FA(5).
6, 32  6-TAMRA dye 
labels were added at three equivalents per dendrimer primary amine, producing G5-
NH2(20)-Ac(82)-FA(5)-6T(3).
9  Finally, the dendrimers were allowed to react with 
excess acetic anhydride to convert any remaining surface amines to acetamide groups, 
resulting in G5-Ac(102)-FA(5)-6T(3).5, 29  Surface functionalization was quantified and 
purity evaluated following each step using several complementary techniques: peak 
integrations from proton nuclear magnetic resonance spectroscopy (1H NMR), molecular 
weight changes from MALDI-TOF mass spectrometry, and using absorbance calibration 
curves with UV–visible (UV–vis) spectroscopy.2, 5, 9, 10, 28, 29 
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2.4 Iron Oxide anoparticle Synthesis 
The following procedures were adapted from the work published by 
Rockenberger et al.33 
2.4.1 Ferric Cupferron Precursor (FeCup3) 
Magnetic stirring was used in the preparation of all solutions unless otherwise 
noted.  In a typical synthesis, a clear, light brown aqueous cupferron solution was 
prepared by dissolving 3.005 g of cupferron in 100 mL deionized tap water (DI water).  A 
280 mL volume of 1% hydrochloric acid was prepared in a separate flask to dissolve 
1.136 g of ferric chloride hexahydrate.  Once the FeCl3·6H2O had completely dissolved 
to form a clear, yellow solution, the solution was further acidified by slowly adding 140 
mL concentrated HCl; the liquid turned a brighter yellow but remained clear.  It was then 
diluted by the slow addition of 525 mL DI water and placed in a refrigerator under 
Parafilm at 4°C for 15 min to cool.  After cooling, the acidic iron chloride solution was 
rapidly stirred while the cupferron solution was added dropwise from a burette.  The 
stirred solution initially became turned clear red.  As more cupferron solution was added, 
the red color grew deeper until the solution became turbid due to the formation of a red-
brown precipitate.  Once addition of the cupferron solution was complete, the precipitate 
was allowed to settle for 15 min before isolating it via Büchner funnel vacuum filtration.  
The solid was washed on the filter paper with several mL of water to remove unreacted 
cupferron.  The filter paper was then placed in a beaker and rinsed thoroughly with 140 
mL of chloroform to extract the solid and form a dark red solution.  A separation funnel 
was used to isolate the organic phase from any residual water.  Crystallization was then 
conducted to obtain pure ferric cupferron (FeCup3).  The organic solution was 
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concentrated to approximately 5 mL using a rotary evaporator with a bath temperature of 
40°C.  Crystallization often spontaneously began upon removal of the flask from the 
rotary evaporator.  If this did not happen, several drops of hexanes were added until white 
wisps appeared in the dark red concentrated solution.  In either case, the resulting mixture 
was placed in the original flask under Parafilm in a refrigerator at 4°C.  After an 
incubation period of around 24 h, the mother liquor was discarded, and the resulting dark 
red FeCup3 crystals were rinsed using cold hexanes, dried under a nitrogen stream, 
collected and weighed.  Typical yields were around 80% with respect to iron. 
2.4.2 Nanoparticle Synthesis 
2.4.2.1 Solution Preparation 
Reaction solutions were generally prepared 24 h prior to actual nanoparticle 
synthesis.  First, an oil bath was set up to stir at 60°C, and a wax bath was set up to stir at 
100°C.  Next, the FeCup3 precursor was dissolved in octylamine to make a clear, dark red 
0.3 M solution; with typical yields, around 10 mL octylamine was required.  The 
resulting solution was transferred into a 50 mL two-neck round-bottom flask containing a 
stir bar; one neck was capped with a septum (preferably white rubber), and a needle valve 
was connected to the other neck.  Finally, 2.5 mL of oleic acid and 8 mL of trioctylamine 
were mixed in a 100 mL two-neck round-bottom flask containing a stir bar to form a 
clear, colorless solution.  One of the flask’s necks was capped with a septum (preferably 
white rubber); a condenser and needle valve were attached to the other neck.  Teflon tape 
was used to secure the connection between the flask and the condenser. 
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Both the 25 mL and 100 mL apparatus were attached to a vacuum line to remove 
residual air and moisture.  The flask containing the solution of oleic acid in trioctylamine 
was set stirring in the 100°C wax bath; the flask containing the FeCup3 solution in 
octylamine was set stirring in the 60°C oil bath.  Drying and degassing were 
accomplished by cracking the needle valves six times: once every 15 min over a 1.5 h 
period.  The FeCup3 solution in octylamine was found to readily bump when heated and 
opened to dynamic vacuum, so special care was taken to slowly open the needle valve 
and not leave it open for too long.  Although there was no discernible change in the color 
or turbidity of the FeCup3 solution following the degassing procedure, the oleic 
acid/trioctylamine solution became light yellow.  After degassing, both apparatus were 
backfilled with Ar once cooled and sealed. 
2.4.2.2 Rapid Injection and Thermal Decomposition 
 
Figure 2.1 - A schematic of the OC-SPIO synthesis. 
 
The flask containing the solution of oleic acid in trioctylamine (Figure 2.1) was 
placed in a sand bath within a heating mantle that was plugged into an adjustable voltage 
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flask at liquid level.  The apparatus was opened to flowing Ar, and condenser water flow 
and rapid stirring were started before supplying heat.  Temperature adjustments were 
made by incremental changes on the voltage transformer dial.  These adjustments were 
made slowly over 2-3 h to ensure thermal equilibration so the thermometer reading 
accurately reflected the liquid temperature.  As the reading neared 250°C a 5 mL all-
plastic syringe was fitted with an 18-gauge needle onto which about a 4.5” piece of thin-
walled Teflon tubing was then threaded.  Once the reading reached 250°C, the needle 
valve stem on the FeCup3 apparatus was removed, and the syringe was purged by 
inserting the tubing into the valve neck and drawing and expelling several aliquots of the 
Ar blanket.  The valve was replaced before removing the septum on the apparatus’ flask 
and using the purged syringe to draw out a 4.8 mL portion of the 0.3 M FeCup3 solution.  
Bubbles were removed by inverting the syringe and expelling the void volume and any 
excess liquid back into the flask; the liquid in the tubing was also drained back in by 
detaching it from the needle with the opposite end still hanging in the flask.  After 
resealing the flask with the septum, the FeCup3 solution was rapidly injected into the hot 
stirring 0.75 M solution of oleic acid in trioctylamine (Figure 2.1).  After reducing the 
temperature to 200°C and aging for 30 minutes, the clear, black reaction liquid was 
allowed to cool to room temperature under argon flow.  Once cool, stirring was stopped, 
and a rare-earth magnet was applied to the flask for 15 minutes to collect and hold any 
magnetic precipitate.  The supernatant was then magnetically decanted into a new flask 
and stored under a nitrogen blanket.  Aliquots were taken as needed from this stock 
solution.  Particles were precipitated by adding 3-fold volume excess of acetone and 
immediately settled by applying a rare-earth magnet.  The magnet was used to hold the 
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particles while decanting the clear, dark brown-yellow supernatant.  Fresh acetone was 
then added, the mixture was agitated, and the particles were again settled using a rare-
earth magnet and held with it while the supernatant was decanted.  This process was 
repeated until the supernatant was clear and colorless.  The cleaned organic-coated 
SPIONs (OC-SPIONs) were dried in a nitrogen stream and then dissolved in chloroform 
for surface modification. 
2.5 Magnetite anoparticle Surface Modification 
 
Figure 2.2 - A schematic of the phase transfer operation of OC-SPIOs leading to DC-SPIOs. 
 
A 3.4 mg portion of G5-Ac(102)-FA(5)-6T(3) was dissolved in 1 mL of DMSO 
(Figure 2.2).  The solution was thoroughly degassed via 5 cycles of standard freeze-
pump-thaw protocol and then placed under flowing Ar.  A syringe purged with nitrogen 
was used to gather a dispersion of 5 mg OC-SPIONs in 1 mL chloroform.  The dendrimer 
solution was heated to 75°C, and the nanoparticles in chloroform were added dropwise at 
a rate of 1.5 mL/min (Figure 2.2).  After the syringe was emptied, the reaction 
temperature was reduced to 60°C, and stirring was continued for 12 hours under steady 
Ar flow.  Heat was then removed, and the clear, dark brown/pink liquid product cooled 
and was transferred to a vial.  The dendrimer-coated SPIONs (DC-SPIONs) were isolated 
75°C - addition 
60°C - aging 










from free dendrimer using precipitation and magnetic separation; this purification was 
performed on individual 150 µL aliquots of the reaction solution to the total volume of 
~1.5 mL.  A threefold volume excess of acetone was added to the aliquot.  The mixture 
was gently agitated, and the resulting precipitate was gathered and held with a rare-earth 
magnet while removing the supernatant using a pipet.  DMSO (150 µL) was added to 
redissolve the particles.  This was followed by precipitation with a 4-fold volume excess 
of acetone, agitation, and magnetic separation as before.  The particles were then dried 
under a nitrogen stream and dissolved in 100 µL water.  The resulting 1 mL of stock 
solution was determined by inductively coupled plasma optical emission spectroscopy 
(ICP-OES) to have an iron concentration of 0.66 mg Fe/mL. 
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CHAPTER 3  
 
CHARACTERIZATIO OF ORGAIC- AD DEDRIMER-
COATED IRO OXIDE AOPARTICLES 
 
3.1 Introduction 
Nanoparticles are complex entities, and their efficacy in biomedical applications 
critically depends on their physicochemical and magnetic characteristics.  These 
properties should thus be determined to both predict their suitability for particular uses 
and facilitate understanding of the results of their application.1, 2  Size, surface 
characteristics and magnetic properties are among the most influential factors influencing 
performance,3 so these were examined using transmission electron microscopy, X-ray 
photoelectron spectroscopy, and a superconducting quantum interference device, 
respectively. 
3.2 Methods 
3.2.1 Transmission Electron Microscopy (TEM) 
Specimens for TEM were prepared by releasing a drop of OC-SPIONs in 
chloroform or a drop of DC-SPION dispersion in water onto 400-mesh copper grids 
coated by ultrathin carbon support films (Ted Pella; Redding, CA).  Once the grids were 
dry, images were acquired using a Philips CM-12 microscope operating at an accelerating 
potential difference of 120 kV. 
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3.2.2 X-ray Photoelectron Spectroscopy (XPS) 
XPS samples were prepared on substrates cut from a sheet of indium foil (0.127 
mm thick, 99.99%; Sigma-Aldrich; Milwaukee, WI).  A drop of OC-SPIONs in 
chloroform or the aqueous DC-SPION dispersion was placed on the foil, and the solvent 
was allowed to evaporate in a fume hood.  Analysis was conducted using an ESCA PHI-
5000C (Physical Electronics; Chanhassen, MN) using Mg Kα X-rays (1253.6 eV) and a 
pass energy of 23.50 eV.  Thorough descriptions of the experimental apparatus have been 
previously published.4, 5 
3.2.3 Superconducting QUantum Interference Device (SQUID) Magnetometry 
A Quantum Design (San Diego, CA) MPMS-5 SQUID magnetometer was used to 
investigate the dependence of sample magnetic moment on applied magnetic field.  The 
specimen was a known volume (~30 µL) of a concentrated aqueous DC-SPION 
dispersion in a quartz tube.  Residual air was removed from the liquid via six cycles of 
standard freeze-pump-thaw techniques before flame-sealing the tube while under vacuum 
using an oxygen/propane type 3A blowpipe with adjustable burn stoichiometry; an OX-2 
(single 0.055”-diameter hole) or OX-1 (single 0.042”-diameter hole) tip worked best. 
Inductively coupled plasma optical emission spectroscopy was employed to 
obtain the normalized magnetic moment with respect to iron.  Poly(methylpentene) 
(PMP) volumetric flasks (Fisher Scientific; Chicago, IL) and ultrapure water with a 
resistivity of at least 18 MΩ·cm were used for all solution preparations.  Iron and yttrium 
1000 ppm elemental standard solutions (100 mL size) were obtained from GFS 
Chemicals (Powell, OH).  A 625 µL aliquot of each of these solutions was added to 
separate 25 mL PMP flasks that were then filled to the line with water to make 25 ppm 
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solutions of Fe and Y.  One mL of the Y solution was added to every sample and 
calibration standard solution prepared to serve as a 1 ppm internal standard.  Calibration 
standards of 5, 1, and 0.1 ppm Fe (all 1 ppm Y) were made along with a 1 ppm Y blank 
(no Fe).  A 50 µL sample of DC-SPION stock solution was diluted to 25 mL by adding 1 
mL of the 25 ppm Y solution and adding water for the remaining volume.  For analysis, 
the 371.029 nm line was used for Y, and the 238.204 nm and 239.562 nm lines were used 
for Fe.  Three replicates were run for each measurement, and the Fe content was taken as 
the average of the mean values for each Fe line obtained over the three replicates. 
3.3 Results and Discussion 
3.3.1 Nanoparticle Synthesis and Surface Modification 
The TEM micrograph in Figure 3.1A shows the structural characteristics of the 
magnetite nanoparticles as synthesized in organic media; the particles are consistent in 
size and shape with a mean diameter of 7.6 ± 0.7 nm (relative standard deviation of 8.9% 
for n = 72).  Such uniformity is desirable since it facilitates determination of the 
connection between the individual particles and their collective behavior.  This is 
especially useful when evaluating their suitability for use in biological applications.  My 
novel phase transfer method leverages the benefits of nanocrystal synthesis in organic 
solvents, namely superior control over phase, shape, size, and size distribution, and 
provided a single step to achieving water solubility and enhanced functionality.  This is 
accomplished using G5 dendrimers functionalized with an average of 102 acetamide 




Figure 3.1 - Transmission electron micrographs of magnetite nanocrystals.  The OC-SPIOs are 
shown in (A); panel (B) displays the DC-SPIOs.  The inset of (B) is a higher-resolution image of the 
same DC-SPIOs clearly showing that size and shape uniformity are maintained.  Although drying 




I hypothesize that the dendrimers effect phase transfer by displacing the fatty acid  
ligands whose carboxylate groups are initially coordinated to the OC-SPIONs’ surfaces.6, 
7  Since every folic acid moiety on the surrounding dendrimers has a free carboxylate 
group and there are multiple folic acids per dendrimer, the free carboxylates of some of 
the folic acid groups likely accomplish this suface exchange and coordinate to the surface 
through multidentate interactions.  Such a linkage between nanoparticle and dendrimer 
would be consistent with the many literature examples of carboxylates coordinating to the 
surfaces of nanoscale metal oxides.8, 9  Furthermore, my parallel attempts to produce a 
control particle using acetylated dendrimers functionalized with 6-TAMRA but without 
folic acid failed to yield stable, water-soluble SPIONs: G5-Ac(107)-6T(3) did not 
produce successful phase transfer whereas treatment with G5-Ac(102)-FA(5)-6T(3) did. 
Figure 3.1B clearly demonstrates that the magnetite nanoparticles’ structural 
quality is maintained upon treatment with G5-Ac(102)-FA(5)-6T(3) and dispersion in 
100 nm 100 nm 
A B 
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water.  It is important to note that there is no guarantee of size and shape uniformity 
being maintained upon phase transfer.10-12  Indeed, the concerns of phase transfer 
operations and place exchange reactions are that significant aggregation and/or changes 
in particle size and shape can occur.  The inset gives a clearer indication that the particles 
do not form fused aggregates even after drying in air.  Further evidence that the iron 
oxide cores remain isolated was demonstrated by lyophilizing and redissolving an aliquot 
of the aqueous DC-SPION suspension. 
 
 
Figure 3.2 - X-ray photoelectron spectroscopy survey scans of (A) OC-SPIOs and (B) DC-SPIOs.  
The insets demonstrate that although no significant changes occur in the iron region of the spectra, 
there is a tremendous increase in nitrogen signal from (A) to (B), corresponding to dendrimers 
displacing the organic shell and binding to the nanoparticles’ surfaces.  Analysis of the nitrogen 1s 
and iron 2p core levels indicates an approximately 20:1 ratio of dendrimers to nanoparticles. 
 
 
The solubility properties of the particles provide strong evidence of surface 
modification by the hydrophilic dendrimers.  Comparing the XPS spectra for the OC-
SPIONs and the DC-SPIONs provides further support for this conclusion.  Figure 3.2 
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(Figure 3.2B) phase-transfer reaction with G5-Ac(102)-FA(5)-6T(3).  The iron regions of 
both scans are nearly identical, but their nitrogen signatures differ significantly.  
Although the nitrogen spectrum in Figure 3.2A shows little more than noise, the same 
region in Figure 3.2B displays a strong signal attributed to the over five-hundred 
nitrogens in the amides and amines that compose the dendrimer backbone.  No distinct 
peaks are seen for the heterocyclic nitrogens in the conjugated folic acid molecules either 
for the coated particles or even for neat G5-Ac(102)-FA(5)-6T(3).  This is not surprising 
considering the approximately 100:3 theoretical ratio of aliphatic to heterocyclic nitrogen 
atoms and the expected overlap of the nitrogen 1s core levels. 








































Figure 3.3 - Magnetization curve for DC-SPIOs.  The data—taken at 37°C using a Quantum Design 




For their ultimate use as targeted contrast agents for MRI, it is critical that the iron 
oxide nanoparticles retain their favorable magnetic properties after coating them with 
dendrimers.  The TEM results from Figure 3.1B demonstrate that the sizes of the DC-
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SPIONs are unchanged from the OC-SPIONs and that the particles do not form fused 
aggregates, strongly suggesting that their magnetic properties would be unchanged.  
SQUID data (Figure 3.3) show that the DC-SPIONs rapidly approach a saturation 
magnetization of 60 emu/g Fe, compared to the bulk value of 90 emu/g Fe.  Their size 
and the negligible hysteresis observed in their magnetic profile suggest that the DC-
SPIONs are superparamagnetic.  Neglecting anisotropy and assuming perfect 
monodispersity permit the DC-SPIONs to be modeled as a collection of magnetic 
moments whose behavior is described by the Langevin function: 








= −     
 (3.1) 
where Ms is the saturation magnetization, H is the applied magnetic field, kB is 
Boltzmann’s constant, T is the absolute temperature, and µ is the magnetic moment of a 
particle in the ensemble.13, 14  This treatment is valid even considering interactions 
between particles.15-17  A fit of Eq. (3.1) to the magnetization data yields the magnetic 
moment for a DC-SPION on the order of 10-16 erg/G or 104 µB, where µB, the Bohr 
magneton, is 9.3x10-21 erg/G.  This demonstrates that the particles are superparamagnetic 
versus merely paramagnetic since paramagnetic moments are generally only a few µB.13  
These factors mean the particles are capable of providing substantial contrast in MR 
images even at modest clinical field strengths. 
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CHAPTER 4  
 
I VITRO EXPERIMETS WITH DEDRIMER-COATED 
IRO OXIDE AOPARTICLES 
 
4.1 Introduction 
Having synthesized and characterized monodisperse, water-soluble magnetite 
nanocrystals protected by functionalized dendrimers, the composite particles’ behavior 
was investigated in vitro.  The main point of the investigation was to demonstrate folic 
acid receptor-mediated targeting of the devices.  It was critical to show binding and/or 
internalization of complete devices by separately tracking properties unique to the 
dendrimer coatings and the iron oxide cores using two distinct but complementary 
methods and showing agreement between the results.  In addition to providing the 
targeting moiety, the dendrimers were also functionalized with 6-TAMRA dye molecules 
for tracking by UV–visible fluorescence using flow cytometry analysis.  The magnetite 
cores were tracked via elemental X-ray fluorescence from constituent iron atoms using a 
novel technique at Argonne National Lab (ANL): X-ray fluorescence (XRF) microscopy. 
4.2 XRF Microscopy and Synchrotron Radiation 
X-ray fluorescence spectroscopy employs X-radiation to liberate core-shell 
electrons from atoms in a sample and create vacancies in their electronic structures.  
Atoms are not stable in such states and will relax by various mechanisms.  In the pathway 
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leveraged by XRF analysis, an electron from a higher orbital drops in energy to fill the 
vacancy.  The energy difference is emitted in the form of an X-ray photon whose energy 
is characteristic of the emitting atom, and the total number of photons emitted is 
proportional to the atom’s abundance in the sample.  Therefore, a sample’s elemental 
content can be quantitatively determined using an energy dispersive detector and 
counting the number of X-ray photons collected at signature energies.  X-ray 
fluorescence microscopy is the application of this technique with high spatial resolution, 
employing an X-ray microbeam to sequentially excite minute regions the sample, 
collecting the emitted photons at each point, and using the data to generate maps of the 
spatial distribution of the elements composing the sample.  Although XRF microscopy 
can, in principle, be performed using standard laboratory X-ray sources, the technique’s 
utility is significantly enhanced using X-rays from a synchrotron, as the high brightness is 
needed to enable high spatial resolution combined with sufficient elemental sensitivity.1 
4.2.1 Synchrotron Radiation and Its Production 
Synchrotron radiation is emitted by charged particles moving at nearly light speed 
and undergoing transverse acceleration.2  The phenomenon naturally occurs for all 
charged particles under such conditions, but it is generally induced for the purposes of 
scientific experimentation using electrons traveling in a storage ring.  Electrons are 
chosen over heavier particles to maximize the radiated power since it varies as the inverse 
fourth power of the particle mass.3 
Before reaching the storage ring, electrons must be liberated from a substance and 
accelerated to the appropriate speed.  This is typically accomplished in two stages.  The 
first stage employs a linear accelerator (linac): generally a cavity subjected to high-
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frequency electromagnetic waves whose electric fields provide the accelerating force.  
Electrons are periodically injected in bunches into this cavity with a timing that ensures 
the electric field they experience is opposite their intended direction of travel.3  Although 
this is an effective method, the cavity length that would be required to accelerate the 
electrons to their final desired speed is practically impossible to implement.  So once the 
electrons leave the linear accelerator, they enter a device called a booster synchrotron in 
which they circulate until reaching the speed desired for the storage ring.  The booster 
synchrotron consists of one or more radio-frequency (RF) cavities and magnets with 
adjustable field strength.  As the electron bunches travel around the booster they emit 
electromagnetic radiation and thus lose energy.  The RF cavities inject energy to negate 
these losses as well as provide a surplus that is added to the particles’ kinetic energy.  As 
the particles’ speed periodically increases, the magnets’ strength must be synchronously 
increased in proportion to this speed to keep the particles traveling on the same fixed 
path.3  This situation is very similar to what occurs in the electrons’ final destination: the 
storage ring.  Bending magnets along the storage ring keep the particles moving along a 
fixed trajectory, but the RF cavities only impart enough energy to replace that which is 
lost as radiation. 
Synchrotron radiation can be extracted along lines tangent to the storage ring 
parallel to the length of the bending magnet, but modern facilities are optimized for the 
use of insertion devices.  Insertion devices (IDs) are arrays of magnets through which the 
electrons pass as they traverse the storage ring.  Without producing any net deflection, 
IDs alter the beam’s path while it is passing through for the enhanced production of 
synchrotron radiation.  There are different kinds of IDs, but undulators are the most 
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important type for XRF microscopy applications.  An undulator is a line of periodic array 
of electromagnets.  The arrangement and strength of the magnets are engineered to force 
electrons traveling through the device to undergo numerous small-amplitude sinusoidal 
oscillations, thus emitting synchrotron radiation many times along its length.  
Constructive interference increases the brightness with a flux output theoretically 
proportional to the square of the number of oscillations.4, 5  The brilliance of the emitted 
light—a parameter describing its intensity and directionality6—at its fundamental 
frequency is about 1000 times that of the output from a bending magnet.7 
4.2.2 XRF Microscopy Using Synchrotron Radiation 
Several of the key characteristics of synchrotron radiation, particularly from 
undulators, make it an ideal source of X-rays for trace elemental analysis of microscopic 
samples.  Because the radiating electrons are moving at relativistic speeds, the 
electromagnetic energy they emit is concentrated into an extremely narrow cone that is 
tangent to the particles’ path.2  The resulting high directionality and high collimation 
afford a very brilliant beam that can deliver high photon flux to small sample areas;1, 8 
this is essential for successful practical application of the tecnhnique.9, 10  Synchrotron X-
ray beams also have quantitatively well-defined characteristics that facilitate the planning 
and execution of experiments and enhance their accuracy and sensitivity.2, 8  Sensitivity is 
also improved by the nearly total linear polarization of the light in the orbital plane, 
which reduces the background of scattered X-rays in certain directions.1, 8, 11  Scattering 
events are minimized along the direction of polarization whereas photoemission is 
isotropic, so the detector can be strategically placed for optimal results. 
 83 
4.2.3 XRF Microscopy at Argonne National Lab (ANL) 
 
Figure 4.1 - A schematic of the experimental setup for X-ray fluorescence microscopy on beamline 2-
ID-E at Advanced Photon Source, Argonne ational Lab.  Image courtesy of and used with 
permission of Dr. Stefan Vogt. 
 
 
The storage ring at ANL is called the Advanced Photon Source (APS),7 and the 
electrons it contains are generated by a hot cathode at 1100ºC.12  The liberated electrons 
are first fed into a linac that brings them up to an energy of 450 MeV for injection into 
the booster synchrotron.12  The electrons leave the booster and enter the storage ring with 
an energy ~7 GeV.13  There are many straight sections along the ring that are fitted with 
insertion devices; the synchrotron radiation that is emitted along the length of these 
sections is allowed to leave the storage ring and pass to stations called beamlines where 
experiments are conducted.  A typical experimental setup for XRF microscopy on 
beamline 2-ID-E and its key components are displayed in Figure 4.1.14  Electrons in the 
storage ring pass through an undulator to generate a beam of synchrotron radiation that is 
monochromatized at the front end of the beamline so it can be focused by the zone plate.  
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To minimize noise from any unfocused light, the beam is further refined using an order-
sorting aperture that only passes focused X-rays.14  The beam finally illuminates the 
sample at a spot size around 0.15 µm2, exciting atoms of the sample’s constituent 
elements in a microscopic area to produce a spectrum of fluorescent X-rays that are 
detected and analyzed.  This process is repeated for the entire region of interest as 
precision stepper motors move the sample so that different areas are irradiated.  Data 
acquired for a range of elements over the entire region of interest are ultimately 
recombined to generate elemental maps. 
4.3 Reagents and Materials 
Reagents were used as obtained from commercial sources.  ProLong Gold with 
DAPI was from Molecular Probes, Inc. (Eugene, OR).  Epithelial cancer cells of the KB 
line were obtained from American Type Culture Collection (ATCC; Rockville, MD); Dr. 
J. Mulé at the University of Michigan kindly proffered the head and neck squamous cell 
carcinoma line, UM-SCC-38.15  Cell culture media, antibiotics, and supplies were 
purchased from Gibco BRL (Gaithersburg, MD). 
4.4 Methods 
4.4.1 Cell Culture 
Human epidermoid carcinoma cells (KB) and squamous carcinoma cells (UM-
SCC-38) were maintained at 37°C and 5% CO2 in RPMI 1640 media supplemented with 
10% heat-inactivated fetal bovine serum (FBS) and 1% penicillin/streptomycin.  While 
the UM-SCC-38 cells were maintained in folate-rich media, the KB cell batch was 
cultured as two distinct populations by growing one half of the batch in folate-rich media 
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and the other half in folate-deficient media.  Although KB cells express the folate 
receptor in normal media (KB-FAR), the receptor density increases on cells grown in 
environments with low folic acid concentration (KB-FAR+, upregulated).16-19  To study 
the targeting capabilities of the dendrimer-coated magnetic nanoparticles, KB-FAR, KB-
FAR+, and UM-SCC-38 cells were seeded in 24-well plates with 500 µL of serum-free 
media and allowed to grow into a monolayer over a 48-hour period.  The neat media were 
aspirated and replaced by 200 µL media with dendrimer-coated nanoparticle 
concentrations of 50, 100 and 200 nM in separate wells for 24-hour incubation; 200 nM 
G5-Ac(102)-FA(5)-6T(3) served as the control.  Wells for KB-FAR were supplemented 
with folic acid at a final concentration of 40 µM; blocking studies of KB-FAR+ by free 
folate were conducted via 15-minute pre-incubation at the same concentration.  One-hour 
incubation was performed the next day using an identical setup on the other halves of the 
same plates such that the cells from both conditions could be simultaneously harvested.  
Every condition for the two time points had two replicates: one for flow analysis and the 
other for iron content measurements.  Once incubation was complete, the media were 
aspirated; the cells were rinsed twice with phosphate-buffered saline (PBS) and were 
detached by incubating in trypsin-EDTA for 15 minutes.  The content of each well was 
collected in a separate flow tube with complete media being added to halt trypsin’s 
enzymatic activity.  The resulting suspensions were then centrifuged for 5 minutes at 
2000 rpm to form cell pellets.  After aspirating the supernatants, 500 µL fresh PBS was 
added to each tube, and the tubes were agitated to form suspensions before repeating 
centrifugation.  Each tube’s supernatant was aspirated, and 500 µL of a 2% buffered 
paraformaldehyde solution was added to each pellet to fix the cells.  The pellets were 
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agitated into suspension and allowed to sit for 15 minutes before centrifugation.  
Aspiration, PBS washing, and centrifugation were performed twice before ultimately 
suspending the fixed cells in 500 µL neat PBS. 
4.4.2 Flow Cytometry 
Flow cytometry was conducted at the University of Michigan Cancer Center (Ann 
Arbor, MI) on a FACSDiVa high-speed cell sorter (Becton, Dickinson & Co.; Franklin 
Lakes, NJ) using an argon laser to excite the 6-TAMRA labels.  Cell samples were 
prepared for analysis as already described. 
4.4.3 Confocal Microscopy 
KB KB-FAR+ cells were plated in glass-bottomed Petri dishes with folate-
deficient media.  Each dish’s media were aspirated and replaced by 500 µL of the 
appropriate concentration of DC-SPIONs or G5-Ac(102)-FA(5)-6T(3) in serum-free 
media.  Incubation was conducted for 1 hour at 37ºC.  All media were aspirated; the cells 
were washed twice with 1 mL of PBS and then fixed by incubation in 1 mL 2% buffered 
paraformaldehyde for 10 minutes at room temperature.  Aspiration and PBS washing 
were again conducted twice.  After aspirating the final PBS wash, ProLong Gold—an 
antifade reagent with DAPI to stain nuclei—was added.  Confocal experiments were 
conducted on a Zeiss LSM 510 confocal microscope using a C-Apochromat 63x 
objective with a 1.2 NA and water immersion.  Each image includes a color layer of red 
fluorescence from the 6-TAMRA, blue fluorescence from the DAPI, and differential 
interference contrast (DIC) of all cells in view.  6-TAMRA images were acquired using 
HeNe laser excitation at 543nm, with emission detected at wavelengths >560nm.  DAPI 
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images were acquired using Ar laser excitation at 364nm, with emission detected at 
wavelengths between 385 and 470nm. 
4.4.4 X-ray Fluorescence (XRF) Microscopy 
Cell samples for elemental analysis were prepared on silicon nitride (Si3N4) 
windows (membrane thickness: 500 nm; Silson Ltd.; Blisworth, Northampton, England).  
A drop of fixed cells suspended in PBS was deposited on the window and allowed to dry 
in a biological safety cabinet.  Several water rinses were then conducted to remove salt 
crystals remaining from the evaporated buffer since the crystals make it difficult to locate 
target cells in addition to raising the background level of fluorescent X-rays.9  After 
thoroughly drying, the Si3N4 windows were collected and placed into a desiccator for 
storage and transportation to the Advanced Photon Source (APS; Argonne, IL).  Once at 
the APS the windows were mounted on kinematic sample holders.  Cells of interest were 
located on the Si3N4 windows using a visible light microscope (Leica DMXRE; Leica 
Microsystems; Wetzlar, Germany) equipped with a motorized, high-precision x/y-stage 
(Ludl Bioprecision; Hawthorne, NY).  The cells were selected from random locations on 
the silicon nitride windows and inspected to verify that they had remained intact during 
sample preparation.  Any burst cells were eliminated as candidates for XRF analysis.  
Another cell was then randomly selected and observed for integrity until the desired total 
was reached.  It should be noted that there are no evident morphological differences 
between cells with high iron content versus cells with low iron content.  Specimen 
positions were recorded and used to locate the same cells for elemental analysis via X-ray 
fluorescence on the 2-ID-E beamline at the APS.  Samples were illuminated with a 10 
keV X-ray beam focused to a 0.3 µm x 0.5 µm spot using Fresnel zone plates (Xradia; 
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Concord, CA).  X-ray fluorescence corresponding to elements with atomic number Z = 
13 (Al) through Z = 30 (Zn) was detected using an Ultra-LEGe energy dispersive Ge-
detector (Be window thickness: 24 µm; single-element area: 100 mm2; Canberra; 
Meriden, CT) as the sample was raster-scanned through the beam spot.  A complete X-
ray fluorescence spectrum was acquired at every scan position for subsequent processing.  
Elemental concentrations were calculated using thin-film samples NBS-1832 and NBS-
1833 from the National Institute of Standards and Technology (NIST; Gaithersburg, MD) 
as calibration standards.  MAPS software—developed by Stefan Vogt and Martin de 
Jonge—was used to evaluate all acquired spectra, produce elemental maps, and calculate 
iron content per cell.20 
4.5 Results and Discussion 
4.5.1 KB Cells 
KB cells are a human epidermoid carcinoma having a variable level of expression 
of receptors for the vitamin, folic acid (FA).  This variation can be induced by simply 
varying the concentration of FA in the cells’ growth media and allowing time for the cells 
to adjust.  Normal KB cells (KB-FAR) have a minimal expression of the folic acid 
receptor when maintained in FA-rich media.  However, the cells will upregulate their 
folic-acid-receptor expression when starved of the vitamin.16-19  They overexpress the 
receptor (KB-FAR+) to increase their chances of proliferation.  With less FA available in 
their environment due to its lower presence, competition for the vitamin with other cells, 
or some combination of factors, KB cells are more likely to survive by enhancing folic-
acid-receptor expression.  It is interesting to note that the process is dynamic and 
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reversible: normal KB cells can be programmed to upregulate and returned to normal 
repeatedly by appropriately adjusting the presence of FA in their growth media.  These 
properties make the KB line ideal for use as a tumor model to assess folic-acid-mediated 
targeting; that is why they were used in this study and in other work done by our group. 
4.5.2 UM-SCC-38 Cells 
UM-SCC-38 is a squamous cell carcinoma line developed at the University of 
Michigan that does not express folic acid receptors.15  Therefore, it provides a useful 
negative control—in addition to normal KB cells—to elucidate the intrinsic binding of 
DC-SPIONs. 
4.5.3 Fluorescence Data 
 
Figure 4.2 - Flow cytometry data for KB cells incubated with DC-SPIOs and the corresponding 
controls.  Error bars indicate the standard error of the mean.  Panel (A) shows binding saturation for 
KB-FAR+ cells with DC-SPIOs and a slight increase in nonspecific binding for KB-FAR cells over 
the concentration range.  Data in panel (B) implicate the folate receptor as the binding mediator 
since cells incubated with free folic acid before DC-SPIO addition exhibit significantly reduced 
fluorescence.  Free folic acid added in large excess occupies the cells’ receptors for the vitamin and 
thus inhibits subsequent cell interaction with DC-SPIOs. 
 
 


















































































































The 6-TAMRA dye molecules present in the DC-SPIONs were used to track 
particle association with the KB cells over various experimental conditions.  Samples 
were sorted using flow cytometry, and data among groups were compared to investigate 
receptor-mediated targeting of the devices.  The results shown in Figure 4.2A 
demonstrate successful targeted binding and/or uptake of the devices as the fluorescence 
intensity is much higher for KB-FAR+ than for KB-FAR.  The saturation seen for KB-
FAR+ also suggests site-specific binding versus non-specific interactions.  Similar 
saturation data were previously observed for the FA-targeted dendrimers alone.18, 21, 22  
The internal dendrimer control for the current experiments, consisting of G5-Ac(102)-
FA(5)-6T(3), showed identical behavior to the DC-SPIONs (Figure 4.2B).  Data from the 
blocking studies (Figure 4.2B) confirm site-specific binding and clearly implicate the 
folate receptor as the means of cell-particle interaction.  A vast excess of free folic acid in 
the growth media prior to treatment with DC-SPIONs occupies the KB cells’ FA 
receptors, thus inhibiting interaction with the FA ligands.  The role of FA-receptor 
targeting was further explored by conducting a comparative study using the KB cell line 
and a cell line that does not express FA receptors, UM-SCC-38.15  The KB-FAR+ cells 
showed a 5.7-fold increase in mean fluorescence whereas the UM-SCC-38 cells showed 
no increase in mean fluorescence. 
4.5.4 Iron Content Analysis 
XRF microscopy was used to determine cellular iron content and to confirm that 
targeting of the DC-SPIONs caused enhanced binding and/or uptake of iron into the cells 
as opposed to only binding and/or uptake of the dendrimers themselves.  The mean data 










































Figure 4.3 - Average cellular iron content as determined by XRF microscopy for different samples.  
Error bars indicate the standard error of the mean.  The largest amount of DC-SPIOs was clearly 
delivered to KB-FAR+ cells.  As expected from the flow cytometry data, KB-FAR cells exhibited 
significantly lower iron content than KB-FAR+ cells although the level was higher than that of KB-
FAR+ blocked cells and the blank control.  Statistical analysis using Mann-Whitney U tests showed 
the iron contents of the KB-FAR+ and KB-FAR+ blocked populations and the KB-FAR+ and control 
populations to be significantly different with 99% confidence.  Similarly, the iron contents of the KB-
FAR+ and KB-FAR populations are significantly different with 80% confidence.  Taken together, 




highest iron loading while KB-FAR+ blocked and the blank control were the lowest and 
exhibited identical content to within experimental error.  One picogram of iron translates 
to approximately 106 particles and—assuming a cell volume of 3.5 pL—a corresponding 
average cellular concentration of ~475 nM particles or ~5 mM Fe.  For the 50 nM KB-
FAR+ DC-SPION condition this means that between 5 and 10% of the available iron as 
nanoparticles was bound to or taken up by the cells. 
In this study, I report on two methods for measuring the uptake of the DC-
SPIONs into the cells and quantification at the individual cell level in both cases.  
Receptor-mediated targeting of DC-SPIONs is strongly supported by both iron XRF 
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microscopy and 6-TAMRA fluorescence.  Details for the entire collection of cells 
analyzed using XRF microscopy are shown in Figure 4.4.  A striking aspect of this figure 
is the large degree of variation in iron content per cell.  However, this degree of variation  
 
 
Figure 4.4 - Iron content for the 17 cells from each experimental group of 50 nM DC-SPIO 
incubation analyzed by XRF microscopy.  The primary abscissa (bottom) shows actual iron content 
in picograms, while the secondary abscissa (top) depicts the equivalent number of DC-SPIOs 
corresponding to a given mass of iron.  There are about 10
6
 DC-SPIOs in one picogram of iron.  





is consistent with the distribution of uptake measured for the large populations of cells by 
flow cytometry as shown in Figure 4.5.  Although direct comparisons between XRF 
microscopy and flow cytometry data are obfuscated by several factors, it is still useful to 
numerically express and analyze the widths of the data distributions observed from these 
two techniques in this study to at least illustrate qualitative similarities in their variations.  
The range of the average values for uptake as measured by fluorescence intensity is 
typically given as the standard error of the mean (SEM).  For the data reported in Figure 
4.5 this yields 2400 ± 20 (0.83% relative SEM, n = 9385) and 2400 ± 20 (0.83% relative 
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Figure 4.5 - Flow cytometry data distributions for G5-Ac(102)-FA(5)-6T(3) alone (A) and for the 
same dendrimers coupled to magnetite nanoparticles, DC-SPIO (B).  ote that the abscissa is a log 
scale for 6-TAMRA fluorescent intensity, and the ordinate is a linear scale for counts.  The 
distributions are quantitatively identical and reveal a large variation in binding through their ~75% 
relative standard deviations. 
 
 
SEM, n = 9324) for the targeted dendrimer alone and for the DC-SPIONs, respectively.  
However, considering the standard deviations (SD) of these data one obtains 2400 ± 1800  
(75% relative SD) and 2400 ± 1800 (75% relative SD).  The relative SEM and relative 
SD for the DC-SPIONs from the flow data can be compared to that obtained by XRF 
microscopy for the 17 KB-FAR+ cells, which are 28% (180 ± 50 fg Fe/cell) and 100% 
(200 ± 200 fg Fe/cell), respectively.  The elevated values for the SEM and SD for the 
XRF microscopy experiments versus the flow cytometry experiments are attributable to 
the much smaller number of cells measured by this method as compared to flow 
cytometry.  Non-parametric methods are required for statistical analysis since my 
samples are small and fail both the F-test for equal variances and the Shapiro-Wilks test 
for normality.  Using Mann-Whitney U tests reveals that the KB-FAR+ population’s iron 
content is significantly different from those of the KB-FAR+ blocked, KB-FAR, and 
control populations with 99%, 80%, and 99% confidence, respectively. 
Mindful of the data distribution, it is interesting to compare representative XRF 
microscopy images (iron maps) for cells from each population as depicted in Figure 4.6.  
A B 
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Hot spots—localized masses of iron—that are substantially greater than the cell’s 
inherent iron content are evident in the upregulated cells (Figure 4.6A).  All upregulated 
cells with high nanoparticle content display these hot spots whereas similar KB-FAR+ 
blocked (Figure 4.6B) and KB-FAR (Figure 4.6C) cells show less localized distributions. 
 
 
Figure 4.6 - Representative false-color XRF microscopy images showing iron content for a KB cell 
from each of four populations: (A) KB-FAR+ with 50nM DC-SPIOs, (B) KB-FAR+ with 50nM DC-
SPIOs + free FA, (C) KB-FAR with 50nM DC-SPIOs, and (D) untreated control.  All incubations 
were for 1 h.  The qualitative feature of localized points of high iron concentration in (A) is obvious; 
these pockets overwhelm the signal from the cell’s endogenous iron background. 
 
 
With an average of 60 molecules of 6-TAMRA per DC-SPION and 106 DC-SPIONs per 
picogram of iron, the amount of iron in these cells corresponds to several million 6-
TAMRA molecules, which is well above the estimated optical detection threshold of 104 
dye molecules.  Furthermore, the punctate distribution of iron observed in the high-iron 
KB-FAR+ cells is similar to the clustering of fluorescence seen in the central-slice 
confocal microscopy images (Figure 4.7) and suggests DC-SPIONs are contained within 
intracellular vesicles.23  Additional evidence for internalization is provided via analysis 
revealing a high autocorrelation between zinc and iron.  This is significant since zinc is a 
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transition metal typically associated with the clathrin-coated pits that are part of the 
receptor-mediated endocytosis pathway.24  Furthermore, analysis of z-stack confocal 
microscopy images for 50 nM DC-SPIONs (Figure 4.8, column A) and 100 nM G5-
Ac(102)-FA(5)-6T(3) (Figure 4.8, column B) shows that the majority of the fluorescence 
from the nanoparticles occurs in the middle of the cells versus their tops or bottoms.  
Thus both G5-Ac(102)-FA(5)-6T(3) alone and the composite DC-SPIONs are 
undoubtedly internalized by the cells. 
 
 
Figure 4.7 - Confocal microscopy images of five experimental conditions demonstrating 
internalization of DC-SPIOs; scale bars are 40 µm.  All images are for KB cells after 1 h incubation 
at 37ºC.  uclei are visible in blue due to DAPI staining; red fluorescence comes from the 6-TAMRA 
dye conjugated to neat dendrimers and dendrimers on the surface of DC-SPIOs.  The PBS control 
for KB-FAR+ (A) shows only background fluorescence, and the KB-FAR+ blocked sample (B) 
exhibits a signal just slightly above this background.  Whereas the signal for neat G5-Ac(102)-FA(5)-
6T(3) with KB-FAR+ (C) is largely concentrated on the cells’ exteriors, the fluorescence for 50 nM 
(D) and 100 nM (E) DC-SPIOs is clearly intracellular and appears in clusters, correlating nicely 
with the XRF microscopy data for iron.  Images taken by Christopher V. Kelly. 




Figure 4.8 - Confocal microscopy z-stacks depicting internalization of 50 nM DC-SPIOs (column 
A); the positive control using neat 100 nM G5-Ac(102)-FA(5)-6T(3) is also shown for comparison 
(column B).  Slices were taken from the sample dish surface (BOTTOM) to the top of the cellular 
monolayer (TOP); consecutive images in each column are separated by 2 microns.  The enhanced 
fluorescence for the 50 nM DC-SPIOs seen in the middle of the stack shows that the majority of 
them are within the cells versus bound to the surfaces.  Images taken by Christopher V. Kelly. 
 97 
The data presented in this thesis employing DC-SPIONs provide a unique 
perspective on uptake distribution because iron is quantified on the cellular level and 
correlated to the entire population of cells characterized by flow cytometry.  Previous 
publications on the topic of targeted delivery of iron oxide particles report intracellular 
iron content based on acid digestion of bulk samples and subsequent analysis by 
inductively coupled plasma optical emission spectroscopy (ICP-OES),25-29 atomic 
emission spectroscopy (AES),30 or colorimetric assay.31  The reported values vary widely.  
Kresse and co-workers indicate uptake of around 2.8 pg Fe/cell for SPIONs targeted to 
human epidermoid carcinoma cells (A 431) using the iron chelating protein, transferrin, 
following 2 hours of incubation.30  Leuschner and collaborators report approximately 150 
pg Fe/cell after 30 minutes of incubating genetically modified human breast cancer cells 
(MDA-MB-435S) with SPIONs at a concentration of 0.3 mg Fe/mL; the particles 
accomplished specific binding via luteinizing hormone releasing hormone (LHRH) 
moieties grafted on their surfaces.31  Finally, Zhang et al. have targeted SPIONs using 
methotrexate (MTX), yielding about 43, 35, and 70 pg Fe/cell for 9L glioma, human 
cervical adenocarcinoma (HeLa), and human breast cancer cells (MCF-7), respectively, 
after 2 hours of incubation.25, 26  They have also employed folic acid as a ligand to target 
SPIONs to HeLa and BT20 cells.  Uptake of approximately 1.4 pg Fe/cell was achieved 
for HeLa cells after 4 hours of incubation.27  The first study for BT20 cells showed up to 
85 pg Fe/cell after 4 days, while subsequent work yielded around 700 pg Fe/cell over the 
same period.28, 29  The above set of previously published measurements all characterize 
iron uptake as an average quantity for a bulk population of cells.  I have shown in this 
research that iron uptake per cell actually varies widely, as would be expected for a FA-
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targeted system.17, 18, 22, 32  It will be of interest for future studies to see if variation in 
uptake for magnetic contrast agents is a common behavior for agents targeted to receptors 
involved in endocytosis. 
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CHAPTER 5  
COCLUSIOS 
5.1 Overview 
The progression of clinical medicine toward earlier detection and treatment of 
disease and perhaps even its prevention requires developing new techniques or refining or 
supplementing current technology.  Magnetic resonance imaging (MRI), currently one of 
the most ubiquitous and powerful contemporary diagnostic methods,1-4 is anticipated to 
be a primary tool in realizing the objectives of this new paradigm.5, 6  It is a noninvasive, 
tomographic technique, without the hazards of ionizing radiation, that provides 
anatomical and physiological data from deep within the body through three-dimensional 
images with nearly microscopic resolution.5, 7-10  Although it was originally hoped that 
MRI would be able to accomplish early detection when used unaided, it soon became 
obvious that its sensitivity is too low when relying upon inherent contrast mechanisms 
within the body.2-4, 11  This prompted the development of contrast agents, such as chelated 
paramagnetic ions and the more recent advent of superparamagnetic particles, 
particularly nanoscale iron oxides. 
Superparamagnetic iron oxide nanoparticles (SPIONs) supersede the 
paramagnetic chelates in many ways.  They have been shown to naturally occur in many 
animals and are currently the only inorganic particulate contrast agents approved for in 
vivo human applications; more formulations are now in Phase-III trials.4, 12, 13  Iron oxides 
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are biodegradable and exhibit neither acute nor chronic toxicity.14-17  SPIONs have a 
large contrast effect per metal center,18 so they are able to generate sufficient contrast in 
low doses versus their paramagnetic counterparts: nM SPIONs (µM Fe) versus mM 
Gd.16, 19, 20  Furthermore, the body has established methods to metabolize the excess iron 
introduced by the particles.15, 18, 21-24 
SPIONs are biocompatible and offer outstanding performance as MRI contrast 
agents, but their full potential can only be realized by directing them to regions of interest 
and having them accumulate there.7, 25, 26  It has been shown that SPIONs can be directed 
in vivo using an external magnet.27-37  However, such a targeting mode has proven 
difficult and requires knowing the desired location a priori.  A more powerful approach 
is the passive targeting method that relies on the judicious adjustment of the particles’ 
physicochemical characteristics to influence their biodistribution following intravenous 
administration.  The particles are sequestered by phagocytic cells in the body and accrue 
mainly in healthy regions of the primary and secondary organs of the reticuloendothelial 
system (RES): the liver, spleen, lymph nodes, and bone marrow.24, 38-55  SPIONs with 
longer circulation can even be found at sites of inflammation following their 
internalization by macrophages56-60 or can gather in tumors via the enhanced permeation 
and retention (EPR) effect.61-64 
Passive targeting has been clinically proven, and magnetic targeting is still being 
pursued, but the “clinician’s dream” is an actively targeted contrast agent with a high 
specificity for cancer markers that accumulates wherever the malignant cells are in the 
body.15, 65  Many approaches to active targeting of SPIONs have been documented, 
including peptides, hormones, antibodies, proteins, therapeutics, and nutrients, such as 
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folic acid (FA).8, 10, 25, 26, 66-107  Antibodies are inherently immunogenic and are also bulky; 
both properties are believed to inhibit internalization of attached structures.  Although 
none of the other approaches suffer from these particular drawbacks, nutrient pathways 
are attractive since they are directly linked to proliferation and thus in principle will cause 
increased uptake of the imaging agent, thereby yielding greater signal for the most 
aggressive tumor cells.  The folic acid receptor (FAR) is overexpressed in a wide variety 
of human cancers, as FA is a key precursor in DNA base synthesis and is thus required 
for tumor cell proliferation.  Folic acid receptors are therefore internalized and recycled 
to the surface for gathering the vitamin,74, 76, 108 a process that is highly advantageous 
since it should enable active loading of SPIONs, leading to MRI contrast enhancement 
that facilitates earlier disease detection.3, 7, 9, 66, 109 
5.2 Summary 
The research presented in this thesis is part of a larger effort to develop 
multimodal nanoparticles: a novel and promising avenue for probing and treating disease 
and evaluating treatment efficacy using a single platform.3, 5, 8, 10, 16, 92-96, 110-112  Its 
foundation is our group’s successful use of poly(amidoamine) (PAMAM) dendrimers 
conjugated with FA to target tumors both in vitro and in vivo.113-123  For the generation 5 
(G5) dendrimers used in this work, an average of five FA molecules per polymer unit 
were covalently attached to leverage the multivalent effect.3, 92, 97, 114, 124-127  On average, 
three molecules of 6-TAMRA (6T) dye were also linked through peptide bonds, and the 
dendrimers’ remaining amine termini were neutralized by capping with acetyl groups 
(Ac).  The dendrimers, denoted G5-Ac(102)-FA(5)-6T(3), were thus specially modified 
to bear folic acid moieties for multivalent targeting, 6-TAMRA dye molecules for 
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tracking via optical fluorescence, and a neutral surface to minimize nonspecific 
interactions with cells.113, 117, 122, 123, 128, 129  These functionalized dendrimers were 
synthesized to transfer high-quality SPIONs from organic to aqueous media, protect 
them, and impart targeting and an optical fluorescent tag in a single step. 
Organic-coated SPIONs (OC-SPIONs) were synthesized by the nonhydrolytic 
procedure published by Rockenberger et al. with a slight but important modification.  
The original synthesis used trioctylamine as a coordinating solvent without any other 
ligands present,130 but particles produced this way were not tractable.  Oleic acid was thus 
added to the reaction mixture as a surfactant; doing so enhanced the resulting particles’ 
stability during purification and handling.  This experimental result agrees with recent 
work that indicates oleic acid is the optimal stabilizer for iron oxide nanoparticles.131, 132 
G5-Ac(102)-FA(5)-6T(3) were used to transfer the hydrophobic OC-SPIONs 
from organic to aqueous media to produce dendrimer-coated SPIONs (DC-SPIONs).  
Transmission electron microscopy (TEM) experiments verified that the DC-SPIONs 
maintained the narrow size and shape distribution afforded by the thermolytic organic 
synthesis.  Superconducting quantum interference device (SQUID) measurements 
demonstrated that the DC-SPIONs were highly magnetic, exhibiting a saturation 
magnetization around 60 emu/g versus the bulk value of 90 emu/g.  Results from X-ray 
photoelectron spectroscopy (XPS) experiments were consistent with a dendrimer coating 
replacing the fatty acid ligands. 
DC-SPIONs were tested for targeting in vitro using KB cells overexpressing the 
folic acid receptor (FAR) as a model system.  Targeting was verified through the 
correlation between cellular association as measured by two distinct and complementary 
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methods: UV–visible (UV–visible) fluorescence for the dendrimers using 6-TAMRA and 
X-ray fluorescence (XRF) microscopy for iron in the iron oxide particles.  Confocal 
microscopy images, including z-stacks, verified that the DC-SPIONs were internalized in 
a manner similar to the free targeted dendrimers.  Previous similar studies either did not 
quantify iron uptake8, 66, 68-71, 106 or did so on bulk samples,25, 26, 72-76 but the work 
presented in this dissertation is unique in demonstrating and quantifying uptake of DC-
SPIONs at the single-cell level using the novel XRF microscopy technique.  Such 
analysis confirms specific targeting of DC-SPIONs and reveals fascinating features and 
variations that cannot be discerned by bulk analysis. 
A wide distribution of uptake was observed when tracking elemental fluorescence 
from iron using XRF microscopy.  However, the breadth of this distribution was 
consistent with that obtained when examining uptake by tracking UV–visible 
fluorescence with flow cytometry.  It is critical to recognize that the abscissa of counts 
versus intensity plots from flow is logarithmic.  Therefore, seemingly narrow, symmetric 
distributions are actually broad and skewed.  Although this is not really significant for 
bulk analyses, it becomes critically important when analyzing individual cells.  It is also 
interesting to note that the width of the distribution obtained for DC-SPIONs is 
indistinguishable from that of free G5-Ac(102)-FA(5)-6T(3): the uptake behavior for the 
dendrimers alone and when they are anchored to the iron oxide nanoparticle surfaces is 
the same. 
5.3 Future Work 
Given the successful in vitro work with DC-SPIONs, animal studies with them 
are worth pursuing.  A small animal’s reticuloendothelial system rapidly clears SPIONs: 
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the blood half-life is generally around 10% of that in a human.16, 133  Hence the contrast 
agent dose for a small animal typically exceeds the average clinical dose for a human, 1 
mg Fe/kg, by an order of magnitude or more.16    Although the majority of studies on 
targeted SPION contrast agents in small animals used amounts consistent with these 
expectations,26, 68-70, 79, 83, 88, 91, 92, 95, 96, 101, 104, 105, 107, 134 several studies report success using 
smaller quantities.8, 86, 87, 93, 97, 99, 106, 135, 136 
Considering the wide variation in the amounts of iron used per kg animal body 
weight (0.25 kg was assumed as the average weight when absolute doses were given), it 
is reasonable to try animal studies at various doses.   Assuming a yield of ~0.7 mg Fe per 
batch of DC-SPIONs, around 0.5 mg Fe would remain for injection after an aliquot was 
taken for SQUID, MRI, TEM, and XPS measurements, and iron content analysis by 
inductively coupled plasma optical emission spectroscopy (ICP-OES).  The product of 
each synthesis should be characterized separately at least until inter-batch consistency has 
been established after multiple repetitions of the protocol.  If necessary to maximize 
usable material, one of the magnetic characterization steps can justifiably be omitted.  
The MRI experiments to assess the r1 and r2 relaxivities of the DC-SPION batch should 
take priority over the SQUID measurements since r1 and r2 are more directly relevant to 
in vivo studies. 
Three dosages should be adequate for a pilot study: 0.125, 0.25, and 0.5 mg Fe.  
For a single mouse at each level, this requires a total of six DC-SPION syntheses.  A 
single OC-SPION preparation will provide plenty of SPIONs; dendrimer availability will 
be the limiting factor.  Following the current protocol, a total of 20.4 mg G5-Ac(102)-
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FA(5)-6T(3) is needed.  The functionalized dendrimers should be prepared in a single 
batch. 
Based on previous work, immunodeficient NOD.CB17-SCID mice (Charles River 
Laboratories; Wilmington, MA) with KB tumor xenografts are suitable models.67, 115  At 
least seven animals are necessary for the pilot study: one untreated control and six 
animals to receive DC-SPIONs, two at each dose.  One of the animals in each treated pair 
will be a negative control, receiving free folic acid prior to DC-SPION injection.  
Injection should be performed once the tumors reach a volume of 0.6 ± 0.15 cm3, 
staggered such that each animal can be imaged at multiple post-injection time points: 1 h, 
4 h, 8 h, 24 h, 48 h, and 7 d. 
 
Moving toward a more proactive approach to medicine is critical to enhance the 
survival of individuals faced with cancer.  Current approaches cannot reliably detect 
cancer early enough to avoid painful and expensive treatments that often fail.  The results 
of this research and many other contemporary studies provide the impetus to continue 
investigating magnetic nanoparticles as actively targeted MRI contrast agents.  
Leveraging the magnetic properties of SPIONs and the flexible surface chemistry of 
dendrimers should be thoroughly investigated to produce multimodal devices, customized 
for individual patients, capable of detecting and treating disease as well as reporting on 
the efficacy of the treatment.  With talented interdisciplinary teams, such as the scientists 
collaborating in the Michigan Nanotechnology Institute for Medicine and Biological 
Sciences (MNiMBS), there is much reason to be hopeful about the future of nanoscience 
and its applications to clinical medicine. 
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